

# KIDNEY WEEK 22

Nov. 3-6 | Orlando, FL



# Onsite Guide



The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney diseases. ASN gratefully acknowledges the following companies for their contributions in 2022.

#### **DIAMOND LEVEL**













#### **PLATINUM LEVEL**









#### **GOLD LEVEL**

Akebia Therapeutics, Inc.
Mallinckrodt Pharmaceuticals
Nipro Medical Corporation
Vertex Pharmaceuticals

#### SILVER LEVEL

Alexion Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Horizon Therapeutics

Natera

Novartis Renalytix Verici Dx

#### **BRONZE LEVEL**

ANI Pharmaceuticals, Inc. Ardelyx Aurinia Pharma U.S. Bayer CareDx CVS Kidney Care DaVita Eurofins Transplant Diagnostics Novo Nordisk OPKO Renal Sanofi

#### TABLE OF CONTENTS

Kidney Week Mobile App	2
Welcome	3
Schedule-at-a-Glance	4
Health and Safety	6
Accreditation, CE Credits, MOC Points	8
Certificates of Attendance for International Participants	9
Day-at-a-Glance: Wednesday, November 2 (Early Programs)	11
Day-at-a-Glance: Thursday, November 3	14
Day-at-a-Glance: Friday, November 4	30
Day-at-a-Glance: Saturday, November 5	46
Scientific Exposition: November 3-5	<b>59</b>
Exhibitor Spotlights: November 3–5	60
Day-at-a-Glance: Sunday, November 6	64
GBTQ+ Owned and Friendly Local Businesses and Organizations	69

#### **Attention US Health Professionals**

To ensure full compliance with the Open Payments (Physician Payments Sunshine Act), a provision of the Patient Protection and Affordable Care Act (PL 111-148) that requires applicable manufacturers and applicable group purchasing organizations to report financial payments made to US physicians and select other US healthcare professionals, including as part of supported ASN activities. ASN reserves the right to provide information to such entities about US physicians, US physician assistants, and US advanced practice nurses (and their spouses) who participate in selected ASN activities. Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain health care providers. ASN makes reasonable attempts to collect and maintain the following information about its US physician members: 1) name and business address, 2) specialty, 3) National Provider Identification (NPI) number, and 4) state(s) professional license number and name of state(s) issuing license.

In the event that ASN receives payment from an applicable sponsor and the sponsor requests the reportable information from ASN, ASN will provide the information under the condition that the sponsor agrees to use the data only for reporting purposes covered under the Act and no other purpose.

US physicians have certain rights under this Act, and more information about these rights can be found at the resources listed below.

To learn more, please go to the US Government's Center for Medicare & Medicaid Services (CMS) website, www.cms.gov/openpayments. Additional information can be found at the American Medical Association's website.





# Download the Meeting Mobile App





# Navigate the meeting like a pro with the meeting mobile app.

- Stay organized with current program, exhibitor, and meeting information.
- Receive important real-time communications from ASN.
- Build a personalized schedule, and bookmark exhibitors.
- Stay in-the-know, and join the social media dialogue.

And much, much more!

**GET THE FREE APP** 







# **Welcome to ASN Kidney Week 2022**

ASN proudly welcomes you to Kidney Week, the world's premier nephrology meeting. At Kidney Week, the world's leading experts share new approaches to health care, research, education, and policy. Participants have opportunities to network with fellow specialists, advance their careers, learn best practices for treating and improving the lives of people with kidney diseases, and collaborate with colleagues from around the world.

Leading the fight against kidney diseases for over 55 years, ASN represents health professionals whose intellectual rigor, integrity, and ingenuity advance kidney research, treatment, and policy and improve the lives of millions of patients.

#### **ASN Council**

Susan E. Quaggin, MD, FASN, *President*Anupam Agarwal, MD, FASN, *Past President*Michelle A. Josephson, MD, FASN, *President-Elect*Deidra C. Crews, MD, MS, FASN, *Secretary*Keisha L. Gibson, MD, MPH, FASN, *Treasurer* 

Linda F. Fried, MD, MPH, FASN, Councilor Crystal A. Gadegbeku, MD, FASN, Councilor Patrick H. Nachman, MD, FASN, Councilor Prabir Roy-Chaudhury, MD, PhD, FASN, Councilor

#### **Kidney Week Education Committee**

Kirk N. Campbell, MD, FASN, Co-Chair Catherine Godson, PhD, Co-Chair George L. Bakris, MD, FASN Moumita Barua, MD Tammy M. Brady, MD, PhD Hui Cai, MD, FASN Kerri L. Cavanaugh, MD, MPH Mark E. Cooper, MBBS, PhD, FASN Stanley D. Crittenden, MD, FASN Alessia Fornoni, MD, PhD, FASN Donald Fraser, MBChB, PhD Lorenzo G. Gallon, MD Anna Greka, MD, PhD Karen A. Griffin, MD, FASN Orlando M. Gutierrez, MD Mark Haas, MD, PhD Jeffrey B. Hodgin, MD, PhD

Pinelopi P. Kapitsinou, MD Beom Seok Kim, MD, PhD Lisa A. Koester Wiedemann, ANP, CNN-NP James P. Lash, MD, FASN Rachel Lennon, MBBS, PhD Tingting Li, MD, MSc, FASN Valeria R. Mas, PhD Precious McCowan, MS Dianne B. McKay, MD Helen McNeill, PhD Patrick T. Murray, MD, FASN Samir M. Parikh, MD, FASN Mark A. Perazella, MD, FASN Catherine Quinlan, MD Wendy L. St. Peter, PharmD, FASN Jason R. Stubbs, MD Volker Vallon, MD, FASN

Kidney Week 2022 educational programming is supported in part from an educational grant from CVS Kidney Care.

# **Schedule-at-a-Glance**

Thursday, November 3	АМ	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session									
BCSS, CPS, TS, SS									
Educational Symposia									
Oral Abstract Sessions									
Poster Sessions						Ask t	he Au	hor	
Scientific Exposition						Exhib	oitor S	potligh	nts
Friday, November 4	АМ	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session									
BCSS, CPS, TS, SS									
Educational Symposia									
Oral Abstract Sessions						High-Impact Clinical Trials			
Poster Sessions						Ask the Author			
Scientific Exposition						Exhibitor Spotlights			
Saturday, November 5	AM	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session									
BCSS, CPS, TS, SS									
Educational Symposia									
Oral Abstract Sessions									
Poster Sessions						Ask the Author			
Scientific Exposition						Exhibitor Spotlights			
Sunday, November 6	AM	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session and ASN Business Meeting									
BCSS, CPS, TS, SS									

#### **LEGEND**

BCSS - Basic/Clinical Science Sessions CPS - Clinical Practice Sessions TS - Translational Sessions

SS - Special Sessions

PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00
													Welc	ome	
	40.00	40.70	100	470	2 2 2	0.70	- 00			470	<b>500</b>	0	Rece	ption	- 00
PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00
PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00
PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00

## **Health and Safety**

#### **Proof of Vaccination**

ALL in-person attendees, staff, vendors, and all other participants are required to provide proof that they are fully vaccinated or will be fully vaccinated for COVID-19 by October 31, 2022, prior to Kidney Week. Because Kidney Week is an international meeting that will take place in the United States, ASN can only recognize vaccines that are fully approved or authorized for use during a public health emergency by the US Food and Drug Administration's Emergency Use Authorization or by the World Health Organization's Emergency Use Listing.

#### **Mask Requirement**

ASN requires masks for all in-person participants, unless they are actively eating or drinking, at all ASN official events, including but not limited to those taking place at the Orange County Convention Center, Hyatt Regency Orlando, other ASN official hotels, and on shuttles.

#### **Physical Distancing**

All in-person participants should expect physical distancing in high-traffic areas, meeting rooms, exhibit floor, and event space in accordance with local and venue regulations. Kidney Week will adhere to capacity standards in accordance with local and state authorities to control the density of the exhibit floor and meeting rooms.

Attendee/audience seating may be modified to allow for compliance with reduced capacity guidelines, and room sets may be modified to accommodate increased spacing. All educational sessions will be recorded and will be available on the Kidney Week virtual platform for both in-person and virtual participants.

#### **Health Monitoring**

All in-person participants should monitor their health before and during Kidney Week. If you are experiencing any symptoms, please do not attend any Kidney Week sessions or events.

#### Assumption of Risk and Waiver of Claims

Participants choosing to attend in-person agreed to the terms of the Assumption of Risk and Waiver of Claims ("Waiver") during the registration process. By agreeing to this Waiver, participants acknowledge that they have made the decision to attend Kidney Week in-person with the full understanding of the inherent risks of such decision and acknowledge and agree to these risks.

#### International Attendance

Please refer to the US Department of State's COVID-19 Travel Information for air travelers to the US. This information continues to be updated and is subject to change.

#### **Food and Beverage**

Water bottles are encouraged, and water coolers are placed in strategic locations throughout the Orange County Convention Center.

Food and beverage events are optional to all participants, and participants may remove masks while actively eating or drinking.

#### **Cleaning and Disinfecting**

Meeting rooms and foyer spaces will be thoroughly cleaned overnight and will be cleaned during the day between sessions.

Restrooms will be regularly and thoroughly cleaned during event hours and include the following touch-free items: soap dispensers, sink faucets, toilet fixtures, paper towel and toilet paper dispensers.

Hand-sanitizer stations will be provided near building entrances, meeting rooms, and lobbies. Touchfree dispensers will be used wherever possible, and a schedule will be established for re-filling the stations.

#### **Hotels**

All hotels within the Kidney Week hotel block have implemented the following measures:

- Heightened cleaning protocols for high-traffic areas such as the front desk, fitness centers, and pools, as well as other high-touch surfaces throughout the hotel, using hospital-grade disinfectant approved by the US Environmental Protection Agency (EPA) to combat the spread of COVID-19.
- Reduced contact at check-in and digital check-in provided.
- Furniture arrangements designed to encourage appropriate social distancing.
- Housekeeping "on-demand" options that allows guests to request delivery of additional toiletries, towels, linens, or coffee without having a housekeeper enter the room.

#### Shuttle Buses

Kidney Week's shuttle bus partner, SEAT Planners, has developed "Clean SEAT" guidelines for the travel and event industry. SEAT Planners partners with local operators that ensure drivers are healthy and symptom-free before leaving the operator's yard. Drivers will clean high-touch areas throughout the day using recommended personal protective equipment (PPE) and disinfectants.

Attendees utilizing shuttle buses will be required to practice posted personal safety guidelines for travelers.

# Accreditation, CE Credits, MOC Points (Annual Meeting, November 3-6)

#### **Learning Objectives**

At the conclusion of this activity, participants will have increased knowledge in the field of nephrology and will be able to:

- 1. Identify recent discoveries in basic, translational, and clinical research in nephrology.
- 2. Construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines.
- Translate recent advances in the areas of general nephrology, dialysis, transplantation, and hypertension into new standards and approaches to clinical care of patients with kidney diseases and related disorders.

#### **Target Audience**

- Physicians
- PhDs and Other Researchers
- Medical and Other Trainees—including medical students, residents, graduate students, post-docs, and fellows
- Nurses and Nurse Practitioners
- Pharmacists
- Physician Assistants
- Other Health Care Professionals

#### **Accreditation Statement**

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



#### **Continuing Medical Education Credits**

AMA CREDIT DESIGNATION STATEMENT - PHYSICIANS

The American Society of Nephrology designates this blended learning activity for a maximum of 75.0 AMA PRA Category 1 Credits $^{\text{TM}}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC CREDIT DESIGNATION STATEMENT – NURSES This CE activity is approved for 75.0 ANCC contact hours.

ACPE CREDIT DESIGNATION STATEMENT – PHARMACISTS This activity has been approved for 75.0 contact hours.

AAPA/NCCPA CREDIT DESIGNATION STATEMENT – PHYSICIAN ASSISTANTS
Physician Assistants may receive a maximum of 75.0 Category 1 credits for completing this activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

ASN values each participant's review and comments on the quality of ASN's educational activities. Please complete the evaluation at www.asn-online.org/elearning by **December 31, 2022**. Instructions are available on the ASN website and at ASN Services in the West Lobby D of the convention center.

**Note:** For Early Program credits, please refer to the program materials.

#### **Maintenance of Certification (MOC) Points**

The Kidney Week Annual Meeting offers MOC Points for American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) Diplomates with the completion of a reflective statement and commitment-to-change questions in this activity's evaluation. Instructions are available on the ASN website and ASN eLearning Center.

#### **MOC Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 75 MOC points in the ABIM Maintenance of Certification (MOC) program; and
- 75 MOC points in the ABP Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

#### Statement from ABIM

This course has been developed as an original and independent educational offering based on the public ABIM examination blueprint and is not approved or endorsed by ABIM. In accordance with ABIM policy, no ABIM Board members have been involved in the development of this course. ASN cannot guarantee that attending this course will result in passing the ABIM examination.

#### **Disclosure Statement**

It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN's sponsored continuing education (CE) activities are expected to provide full disclosure for both themselves and their spouse/partner, and to indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the previous 24 months. Furthermore, ASN requests all faculty to disclose at the time of their lecture any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their presentation. Participants should note that the use of products outside US Food and Drug Administration (FDA)-approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CE, but rather to ensure that ASN CE activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for Kidney Week to complete disclosure forms. Responses are listed on the ASN website, in the meeting platform, and during sessions.

# Certificates of Attendance for International Participants

Early Program participants can pick up printed Certificates of Attendance (not CE certificates for US participants) on Wednesday, November 2 at the programs. Annual Meeting participants can access online Certificates of Attendance (not CE certificates for US participants) from November 3, 2022, through February 3, 2023, at https://show.jspargo.com/asn22/certificateofAttendance/. Certificates are only available if you have picked up your meeting materials or printed your meeting badge onsite. If you have questions, please visit ASN Services in the West Lobby D of the convention center.

# UNITED TO MAKE A DIFFERENCE.



Join the kidney health professionals who are embracing four priorities to move us closer to our goal of a world without kidney diseases.





# DAY-AT-A-GLANCE Wednesday, November 2

#### **Early Programs**

Each Early Program requires separate registration from the Annual Meeting.

#### The following in-person Early Programs do not have onsite registration:

#### Advances in Research Conference: Regenerative Medicine and Bioartificial Kidneys.......W230

7:00 a.m. Onsite Check-In and Continental Breakfast

8:00 a.m. Onsite Sessions

5:00 p.m. Adjourn

#### Fundamentals of Renal Pathology......W222

7:00 a.m. Onsite Check-In and Continental Breakfast

8:00 a.m. Onsite Sessions 5:35 p.m. Adjourn

#### Point-of-Care Ultrasound in Nephrology.......W221

In-kind support is provided by EchoNous, Inc., FUJIFILM Sonosite, Inc., GE Healthcare,

Philips Healthcare North America.

7:00 a.m. Onsite Check-In and Continental Breakfast

8:00 a.m. Onsite Sessions 4:30 p.m. Adjourn

#### The following fully virtual Early Programs do not have onsite activities:

Critical Care Nephrology: 2022 Update Glomerular Diseases: 2022 Update

Support is provided by an educational grant from Travere Therapeutics, Inc.

**Maintenance Dialysis** 

Renal Physiology: Structure and Function in Kidney Health and Disease

Scan the
QR code from
the ScanHunt
tab of the
Kidney Week
2022 app.
Download the
mobile app to
play!

Check out the ScanHunt game in the meeting app for a chance to win a Kidney Week 2023 registration.

Scan various QR codes in the convention center and the Hyatt Regency Orlando to earn points. Participants with 100 or more points will be entered to win one of 3 complimentary registrations.



Search Kidney Week in your app store or scan the QR code here.

# **Community Lounge Events**

Make the most of your time at ASN Kidney Week 2022 with quick, informal sessions about the value of community discussions, networking, and collaboration.

Also enjoy the relaxation area with complimentary massages (first-come, first-served).

# Thursday Nov. 3

**Overview of Communities** 

10:00 – 11:00 a.m.

Profile components, account preferences, navigation tips

Becoming a Community Leader

1 1:00 a.m. – 12:00 p.m.

Engagement strategies, moderation, replies, follow-through

**Mentor Match Program** 

12:00 – 1:00 p.m.

Enrollment basics, search criteria, building relationships

**Communities Office Hours** 

1:00 - 1:30 p.m.

Meet & greets, questions & answers

# Friday Nov. 4

The Art of Discussion

10:00 - 11:00 a.m.

Tips & strategies, best practices, seed questions, quality content

General & Clinical Nephrology Poster Tour 11:00 a.m. – 12:00 p.m. Led by Edgar Lerma, MD, FASN and Roger Rodby, MD, FASN

**Hot Topics** COVID-19, transplantation, dialysis safety

12:00 – 1:00 p.m.

Networking and Collaboration

1:00 – 1:30 p.m.

Leveraging connections, sharing stories, team projects

# Saturday Nov. 5

**Communities Library** 

10:00 – 11:00 a.m.

Keyword searching, studies & reports, credible research

**Early Career Focus** 

11:00 a.m. - 12:00 p.m.

STARS, TREKS, in-training exam, the nephrology match

**Themed Communities** 

12:00 – 1:00 p.m.

Onco-Nephrology, Kidney Transplantation, Women's Health

& Research

**Open Discussion** 

1:00 – 1:30 p.m.

New ideas, future directions, lingering questions

Join an intimate group of your peers as you listen and partake in conversations.



# **Kidney**Cure

Fund it. Find it.

"Receiving funding from KidneyCure not only supports the progression of my research but also confirms that my research is considered valuable to the field."



# Tanecia Mitchell, PhD

**2021-2022 Transition to Independence**Grant Recipient
University of Alabama at Birmingham

The gifted fellows and early-career investigators funded by KidneyCure share your commitment to making a difference for the millions of patients impacted by kidney diseases.

These trailblazers, working across the kidney research spectrum, are finding new paths to conquering diseases, such as Tanecia Mitchell, PhD, whose novel method of measuring dietary oxalate aims to

better understand, prevent, and treat

kidney stone formation.

Your support is crucial to keeping brilliant investigators like Tanecia in the field and on track to making important discoveries.

#### Make a Difference

Use your phone's camera to scan the QR code.



Or visit: www.kidneycure.org/donate

# DAY-AT-A-GLANCE Thursday, November 3

0.00	
8:00 a.m. – 9:30 a.m.	laluana
Joint ASN-National Academy of Medicine Opening Plenary: ASN President's Ad Expert Panel "Preventing the Next Pandemic"	
Expert Parier Preventing the Next Pandemic	W415 Valencia
9:30 a.m. – 2:30 p.m.	
Morning Break (9:30 a.m. – 10:00 a.m.)	West Exhibit Hall D
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)	West Exhibit Hall D
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)	
10:30 a.m. – 12:30 p.m.	
Basic/Clinical Science Sessions	
Big Roles for Thin Limbs	
Podocyte Development, Disease, and Stem Cell Research	W240
Clinical Practice Sessions	
Health Care Equity for All: Improving the Experience of Patients with Kidney Dis	seasesWF1 Tangerine
Nephrology Consult Service in the Hospital: No Rest for the Weary	W415 Valencia
Novel Anticancer Therapies and Hypertension: The Role of the Nephrologist	W311
Personalizing Prescriptions in Hemodialysis: A Path to Safer Care for All	WF2 Tangerine
The Patient Journey with Diabetic Kidney Disease,	
Including the Garabed Eknoyan Endowed Lectureship	W224
Tired of Debating the Limitations of eGFR? Do Your Patients a Favor and Measure	ure GFR! W304
Translational Sessions	
Deep Dive into the Pathophysiology of Kidney Stone Formation	W414
Organ Preservation into the 2020s: The Era of Dynamic Intervention	
Prospects for Gene Therapy in Glomerular Disease,	······
Including the Michelle P. Winn Endowed Lectureship	W320 Chapin
	,
Other Events	
Fellows-in-Training Bowl: Elimination Rounds	West Exhibit Hall D
Reimagining Nephrology Fellowship Training:	
Recommendations from the 2022 ASN Task Force on the Future of Nephrolo	ogy W315
12:45 p.m. – 1:45 p.m.	
Educational Symposia (Hyatt Regency Orlando) – Doors open at 12:30 p.m.	AC L BU V
Hope in ADPKD: Innovation in Therapeutics\	Windermere Ballroom X
IgA Nephropathy: The Role of the Renal Endothelin System and	
Other Therapeutic Implications	Regency Ballroom R
Management of Hyperphosphatemia in Patients with ESKD,	
Especially During the COVID-19 Pandemic	
Updates on Therapeutic Options for Anemia in Kidney Diseases	Regency Ballroom 1
2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
Alternative Animal Models of Kidney Development and Repair	
Applications of Artificial Intelligence to Medical Kidney Biopsy Interpretation	
Cell-to-Cell Chats in the Diabetic Kidney	
Controversies in Phosphorus Homeostasis and Management in CKD	
Metabolism and Kidney Diseases	
Skeletal Muscle: An Underappreciated Target Organ in CKD	W304
Untangling Determinants of AKI Through an -Omics Approach,	W200
Including the Robert W. Schrier Endowed Lectureship	W308

2:00 p.m. – 4:00 p.m. Clinical Practice Sessions
Clinical Practice Sessions
A Look in the Crystal Ball: COVID-19 and the Future of Outpatient DialysisWF2 Tangerine
Case Studies in Glomerular Diseases 2022W320 Chapin
Current Approaches to the Management of Common Cardiorenal SyndromesW307
Novel Treatments for Resistant Hypertension in Advanced CKDW311
What Can Genomic Sequencing Offer People with CKD?W240
Translational Sessions
Future Shock: Transformational Therapies for Kidney Failure
New Directions and Strategies to Improve Hypertension and
Pain Management in CKDW415 Valencia
Special Session
Choose Your Own Adventure: Nephrology Career PathsW314
4:00 p.m. – 4:30 p.m.
Afternoon BreakWest Lobby D, West Lobby E/F, W415 Valencia Foyer, W320 Foyer
4:30 p.m. – 6:00 p.m.
Basic/Clinical Science Sessions
Autosomal Dominant Tubulointerstitial Kidney Disease:
New Diagnostics and TherapiesWF1 Tangerine
Impact of MicroRNAs and Circular RNAs on the Pathogenesis and
Prognosis of Glomerular DiseasesW304
Clinical Practice Sessions
Implementing the Race-Free eGFR Equations in Clinical Practice:
Where Are We Now?WF2 Tangerine
Why Allografts Fail: Clinical, Histopathological, and Molecular Approach to
Chronic Allograft Injury, Including the Barbara T. Murphy Endowed LectureshipWF3 Tangerine
Translational Session
European Nephrology Highlights: Updates from the 2022 ERA CongressW224
Oral Abstract Sessions
AKI Research: Prediction, Diagnosis, RecoveryW230
Dialysis: Patient-Centered Interventions and OutcomesW414
Hypertension and CVD: Epidemiology, Risk Factors, PreventionW240
Pediatric Nephrology: From Bench to BedsideW307
Technology-Based Approaches in NephrologyW308
Transplantation: Basic ResearchW314
Topical Chats
The IQ to Teach QI: Quality Teaching of Quality ImprovementW221A
Promoting Diversity, Inclusivity, and Equity in Patient Care
6:00 p.m. – 7:00 p.m.

Download the meeting app or scan the QR code for more details and updates.



#### Thursday, November 3, 8:00 a.m. - 9:30 a.m.

ASN President's Address, Expert Panel "Preventing the Next Pandemic" .............. W415 Valencia

Joint ASN-National Academy of Medicine Opening Plenary:

ASIN thanks ti	he National Academy of Medicine and Dr. Victor Dzau for assistance with this session.
8:00 a.m.	ASN President's Address – Susan Quaggin
8:25 a.m.	"Preventing the Next Pandemic" Keynote – Peter Hotez
8:45 a.m.	"Preventing the Next Pandemic" Panel – Carlos del Rio (moderator),
	Timothy Evans, Peter Hotez, Jennifer Nuzzo, Reed Tuckson
	Thursday, November 3, 10:30 a.m. – 12:30 p.m.
Bia Roles for	r Thin LimbsW230
	Christine Klemens, Tong Wang
10:30 a.m.	New Insights on Spatial Cortico-Medullary Gene Expression and Osmolality
	Gradients – Christian Hinze
11:00 a.m.	Lessons from Anatomical Organization and Gene Expression Profiles of Thin
	<b>Limbs</b> – Thomas Pannabecker
11:30 a.m.	Function and Regulation of the Tight Junctions of Thin Limbs – Nina Himmerkus
12:00 p.m.	Multiple Functions of Thin Limbs: From Flow Resistor to Urine Concentration –
	Mark Knepper
Podocyte De	evelopment, Disease, and Stem Cell ResearchW240
	Tobias Huber, Oliver Wessely
10:30 a.m.	3D Visualization of the Podocyte Actin Network with Leading-Edge
	Approaches – Hani Suleiman
11:00 a.m.	Defining the Maturation of Kidney Cells with Single-Cell Sequencing and
	Functional Predictions – Ryuichi Nishinakamura
11:30 a.m.	Podocyte Repair After Injury: Reprogramming the Transcriptome –
	Jordan Kreidberg
12:00 p.m.	Podocytes from Amniotic Fluid, Glomeruli on a Chip, and Alport Syndrome –
	Laura Perin
Health Care	Equity for All: Improving the Experience of Patients with
	asesWF1 Tangerine
•	he ASN Diversity, Equity, and Inclusion Committee and ASN Health Care Justice Committee
	with this session.
	ovided by an educational grant from Chinook Therapeutics, Inc.
	Jason Cobb, Tessa Novick
10:30 a.m.	Stony the Road We Trod: Fighting for Kidney Health Justice –
	Orville Newton-Ray Bignall
11:00 a.m.	Framing Discussion of CKD Around Issues Important to Members of the
	LGBTQ+ Community – Suzanne Martin
11:30 a.m.	Why I Decided to Become an Advocate and So Should You – Mukta Baweja
12:00 p.m.	Patient Engagement: Tips, Tricks, and Pitfalls (Panel) – Teri Browne,
	Tanjala Purnell, David Rush

## Thursday, November 3, 10:30 a.m. – 12:30 p.m.

Nephrology (	Consult Service in the Hospital: No Rest for the Weary
Moderators: Li	ili Chan, Roger Rodby
10:30 a.m.	Panicked Call from the Hepatologist: Patient with Cirrhosis Has Anuric AKI and Needs CRRT – Andrew Allegretti
11:00 a.m.	Urgent Consult from Your Oncology Colleague: Pediatric Patient with Lymphoma Has Tumor Lysis Syndrome and AKI – Arwa Nada
11:30 a.m.	Stat Consult from the Cardiac Care Unit: Patient with Advanced Heart Failure Has Diuretic Resistance and AKI – Jeffrey Turner
12:00 p.m.	Midnight Call from the Medical Intensive Care Unit: Patient with Complicated Sepsis on Extracorporeal Membrane Oxygenation Has Developed AKI – J. Pedro Teixeira
	ncer Therapies and Hypertension: The Role of the NephrologistW311
Moderators: K	enar Jhaveri, Sheron Latcha
10:30 a.m.	New-Onset Hypertension in Patients with Cancer Secondary to Cancer Therapies – Gavin Oudit
11:00 a.m.	Mechanisms of Hypertension due to Vascular Endothelial Growth Factor (VEGF) Inhibitors – Vesna Garovic
11:30 a.m.	Hypertension due to Non-VEGF-Pathway Anticancer Therapies – Sandra Herrmann
12:00 p.m.	Distinct Approaches to Diagnosing, Monitoring, and Managing Hypertension in Patients with Cancer – Agnes Kim
	Prescriptions in Hemodialysis: A Path to Safer Care for AllWF2 Tangerine
Moderators: T	ara Chang, Joanna Hudson
10:30 a.m.	Symptoms in Hemodialysis: Advances in Assessment and Management to Reduce Harm – Connie Rhee
11:00 a.m.	Personalizing Electrolytes in the Dialysis Prescription: Is That the Key? – Talat Alp Ikizler
11:30 a.m.	Should We Evaluate and Address Weight at Every Dialysis Treatment? – Jennifer Flythe
12:00 p.m.	Dialysis Modality Selection Counseling Should Not Be Limited to Initiation – Keren Ladin
	ourney with Diabetic Kidney Disease,
Including the	Garabed Eknoyan, MD, Endowed LectureshipW224
ASN gratefully	acknowledges Wadi N. Suki, MD, for support of the Garabed Eknoyan, MD,
Endowed Lectu	reship. ASN thanks the ASN Diabetic Kidney Disease Collaborative Task Force for
assistance with	this session.
Moderators: Ia	n de Boer, Susanne Nicholas
10:30 a.m.	Delay Does Not Mean Denial: A Patient's Experience with DKD – Patrick Gee
11:00 a.m.	Improving Awareness, Detection, and Interventions for Patients with DKD – Amy Mottl
11:30 a.m.	Implementing Goal-Directed Medical Therapies for DKD: The Garabed Eknoyan, MD, Endowed Lectureship – Katherine Tuttle
12:00 p.m.	Getting the Job Done with Value-Based Care for Patients with DKD – Daniel Weiner

## Thursday, November 3, 10:30 a.m. – 12:30 p.m.

<b>Tired of Deba</b>	ting the Limitations of eGFR? Do Your Patients a Favor and Measure GFR!W304
Moderators: H	arold Feldman, Delphine Tuot
10:30 a.m.	Individual-Level Inaccuracy of eGFR and Implications for Clinical Care – Tarig Shafi
11:00 a.m.	GFR Measurement by Plasma Clearance Does Not Require Urine Collection – Natalie Ebert
11:30 a.m.	GFR Measurement by Urinary Clearance Without an Intravenous Infusion – Jesse Seegmiller
12:00 p.m.	Choosing the Best GFR Measurement Technique in Clinical Practice – John Lieske
Deep Dive int	o the Pathophysiology of Kidney Stone FormationW414
Moderators: K	irsten Kusumi, Khashayar Sakhaee
10:30 a.m.	Evolving Understanding of Oxalate Metabolism in Humans – Sonia Fargue
11:00 a.m.	Unraveling the Microstructural Elements of Kidney Stones and Randall Plagues – James Williams
11:30 a.m.	Role of Innate Immunity Pathways in Regulating Stone Formation – Tanecia Mitchell
12:00 p.m.	Contribution of Gut Microbes to Kidney Stone Formation – Michelle Denburg
Organ Preserv	vation into the 2020s: The Era of Dynamic InterventionWF3 Tangerine
Moderators: A	nil Chandraker, Mita Shah
10:30 a.m.	To Pump or Not to Pump: Machine Perfusion versus Cold Storage for Deceased Donor Kidney Transplantation – Markus Selzner
11:00 a.m.	Inflammatory Landscape of the Perfused Kidney: New Interventions and Effects on Outcomes – Annemarie Weissenbacher
11:30 a.m.	Mechanisms of Human Kidney Cold Storage and New Precision Therapies –
12:00 p.m.	Gregory Tietjen  Cryobiology to Stabilize the Donor Organ – Erik Finger
	Gene Therapy in Glomerular Disease,
Including the	Michelle P. Winn, MD, Endowed LectureshipW320 Chapin
ASN gratefully	acknowledges Duke University School of Medicine, the school's Division of Nephrology,
and several inc	lividuals for support of the Michelle P. Winn, MD, Endowed Lectureship.
Moderators: Fi	riedhelm Hildebrandt, Kandai Nozu
10:30 a.m.	Experience from Clinical Trials of Immune Gene Therapies – Waseem Qasim
11:00 a.m.	Targeting the Kidneys with Gene Therapy – Matthew Wilson
11:30 a.m.	Adeno-Associated Virus (AAV) Genome Rescue of Nphs2 in Mice:
	The Michelle P. Winn, MD, Endowed Lectureship – Moin Saleem
12:00 p.m.	Preclinical Gene Therapy Studies in Alport Syndrome Dogs – Mary Nabity
Fellows-in-Tra	aining Bowl: Elimination RoundsWest Exhibit Hall D
	rided by Chinook Therapeutics, Inc.
	ng education credits are not being offered for this activity.
Reimagining	Nephrology Fellowship Training:
	tions from the 2022 ASN Task Force on the Future of NephrologyW315
Note: Continui	ng education credits are not being offered for this activity.

#### Thursday, November 3, 12:45 p.m. - 1:45 p.m.

**Educational Symposia (Hyatt Regency Orlando)** – Doors open at 12:30 p.m. Lunch is provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.

	pathy: The Role of the Renal Endothelin System and
	peutic ImplicationsRegency Ballroom R
	ovided by an educational grant from Travere Therapeutics, Inc.
12:45 p.m.	Introduction – Tingting Li (Moderator)
12:55 p.m.	Proteinuria in IgA Nephropathy: Mechanisms and Clinical Implications –
1.15	Jonathan Barratt
1:15 p.m.	Emerging Therapies in IgA Nephropathy: Targeting the Renal Endothelin
1.25	System and Other Therapies – Richard Lafayette
1:35 p.m.	Questions and Answers
Managemen	t of Hyperphosphatemia in Patients with ESKD,
<b>Especially Du</b>	uring the COVID-19 PandemicRegency Ballroom S
Support is pro	ovided by an educational grant from Fresenius Medical Care.
12:45 p.m.	Introduction: Phosphate Homeostasis and Hyperphosphatemia Management –
	Elvira Gosmanova (Moderator)
12:55 p.m.	Update on Hyperphosphatemia Management in Patients with ESKD, Especially
	During the COVID-19 Pandemic – Michal Melamed
1:15 p.m.	Organ Cross-Talk in Phosphate Homeostasis – Sharon Moe
1:35 p.m.	Questions and Answers
Updates on	Therapeutic Options for Anemia in Kidney Diseases Regency Ballroom T
Support is pro	ovided by an educational grant from GlaxoSmithKline.
12:45 p.m.	Introduction – Fredric Finkelstein (Moderator)
12:55 p.m.	Management of Anemia in Nondialysis CKD: Current Recommendations – Bruce Robinson
1:15 p.m.	Efficacy and Cardiovascular Safety of Hypoxia-Inducible Factor-Prolyl
	Hydroxylase Inhibitors – Nupur Gupta
1:35 p.m.	Questions and Answers
	Thursday, November 3, 2:00 p.m. – 4:00 p.m.
	Animal Models of Kidney Development and RepairWF1 Tangerine
	ain Drummond, Leif Oxburgh
2:00 p.m.	Rhesus Macaque as a Model for Human Lateral Branch Nephrogenesis – Meredith Schuh
2:30 p.m.	Spiny Mouse as a Model for Kidney Regeneration – Daryl Okamura
3:00 p.m.	Using Zebrafish to Model Kidney Development – Rebecca Wingert
3:30 p.m.	Using Frogs to Understand Cystic Kidney Disease – Oliver Wessely

<b>Applications</b>	of Artificial Intelligence to Medical Kidney Biopsy InterpretationW315
Moderators: I	Laura Barisoni, Avi Rosenberg
2:00 p.m.	Image Analysis in the Quantitation of Interstitial Fibrosis and
	Glomerulosclerosis – Alton Farris
2:30 p.m.	Computational Segmentation and Quantification in Diabetic Nephropathy –
	Pinaki Sarder
3:00 p.m.	Deep Learning Classification of Kidney Transplant Pathology – Peter Boor
3:30 p.m.	High-Throughput Quality Control, Annotation, and Labeling in Kidney Digital
•	Pathology Repositories for Biomarker Discovery – Andrew Janowczyk

## Thursday, November 3, 2:00 p.m. – 4:00 p.m.

Cell-to-Cell C	hats in the Diabetic KidneyW224
	rided by an educational grant from Travere Therapeutics, Inc.
	lichael Donnan, Agnes Fogo
2:00 p.m.	Visceral to Parietal Cell Chats – Sandeep Mallipattu
2:30 p.m.	Communicating Through Nanotubules – Federica Barutta
3:00 p.m.	Endothelial Cells to Podocytes and Back – Ilse Daehn
3:30 p.m.	Can Tubules Influence Glomerular Cell Function? – Roderick Tan
Controversies	in Phosphorus Homeostasis and Management in CKDW414
Moderators: K	enneth White, Myles Wolf
2:00 p.m.	Soluble Klotho Has Direct Actions That Regulate Phosphorus Homeostasis – Li-Li Hsiao
2:30 p.m.	Soluble Klotho Does Not Have Direct Actions That Regulate Phosphorus Homeostasis – Christian Faul
3:00 p.m.	Reducing Dietary Phosphorus Intake Is Critical for Preventing CKD-MBD – Annabel Biruete
3:30 p.m.	Reducing Dietary Phosphorus Intake Is Counterproductive in Preventing CKD-MBD – Kathleen Hill Gallant
Metabolism a	nd Kidney DiseasesW230
	anie Park, Sian Piret
2:00 p.m.	Metabolic Decision in Development and Disease: Overview in Kidney
·	Perspective – Scott Summers
2:30 p.m.	Renal Metabolism and Hypertension – Mingyu Liang
3:00 p.m.	Fructose Metabolism in Kidney Diseases – Miguel Lanaspa
3:30 p.m.	Metabolic Reprogramming in PKD – Alessandra Boletta
Skeletal Musc	le: An Underappreciated Target Organ in CKDW304
	lara Bohm, Hui Cai
2:00 p.m.	Mitochondrial Health and Muscle Bioenergetics in CKD – Baback Roshanravan
2:30 p.m.	Skeletal Muscle Regeneration and Fibrosis in CKD and Dialysis –
	Matthew Abramowitz
3:00 p.m.	Muscle Wasting, Autophagy, and CKD – Xiaonan Wang
3:30 p.m.	Insights into Muscle-Kidney Cross-Talk – Tobias Huber
Untangling D	eterminants of AKI Through an -Omics Approach,
Including the	Robert W. Schrier Endowed LectureshipW308
ASN gratefully	acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and
	uals for support of the Robert W. Schrier, MD, Endowed Lectureship.
Moderators: Eu	ugene Rhee, Tomokazu Souma
2:00 p.m.	Spatial Transcriptomics in AKI – Eryn Dixon
2:30 p.m.	Proteomics in AKI – Roman-Ulrich Mueller
3:00 p.m.	Metabolomics in AKI – Samir Parikh
3:30 p.m.	Integrating Analysis of Animal Models and Human Biopsies to Better
•	Understand AKI: The Robert W. Schrier, MD, Endowed Lectureship –
	Lloyd Cantley

## Thursday, November 3, 2:00 p.m. – 4:00 p.m.

A Look in the	Crystal Ball: COVID-19 and the Future of Outpatient DialysisWF2 Tangerine
ASN thanks the	e ASN COVID-19 Response Team for assistance with this session.
Moderators: Br	rigitte Schiller, Jeffrey Silberzweig
2:00 p.m.	Dialysis Facility Staffing in the Wake of COVID-19 – Jeffrey Hymes
2:30 p.m.	Vaccine Requirements: Are Mandates Ethical? – Olivia Kates
3:00 p.m.	ESRD Network Roles: Patient Resources and Regulatory – Kamyar Kalantar-Zadeh
3:30 p.m.	Most Important Good and Bad Impacts of COVID in Dialysis – Dawn Edwards
Case Studies i	n Glomerular Diseases 2022W320 Chapin
Support is prov	ided by an educational grant from Travere Therapeutics, Inc.
	eal Herlitz, Brad Rovin
2:00 p.m.	Case 1 – Richard Lafayette
2:30 p.m.	Case 2 – Keisha Gibson
3:00 p.m.	Case 3 – Dawn Caster
•	Case 4 – Jonathan Barratt
	paches to the Management of Common Cardiorenal SyndromesW307
	see Bouchard, Anitha Vijayan
2:00 p.m.	Prevention and Management of AKI in Acute Heart Failure: The Importance of
	Decongestion – Janani Rangaswami
2:30 p.m.	Prevention of Contrast-Associated AKI in Patients Undergoing Coronary
	Angiography – Neesh Pannu
3:00 p.m.	Prevention and Management of AKI in Patients Undergoing Cardiac Surgery –
	Andrew Shaw
3:30 p.m.	"Permissive AKI" Is the Price of Success When Using SGLT2 Inhibitors in
·	Cardiorenal Syndromes – Adeera Levin
Novel Treatm	ents for Resistant Hypertension in Advanced CKDW311
	eorge Bakris, Karen Griffin
2:00 p.m.	Nonsteroidal Mineralocorticoid Receptor Blocker (KBP-5074) for Hypertension
2.00 p.m.	in Stage 4 CKD – Pablo Pergola
2:30 p.m.	Combined Endothelin A and B Antagonists in Patients with Stage 4 CKD –
2.30 p.m.	Ernesto Schiffrin
2,00 n m	
3:00 p.m.	Effects of Firibastat, a First-in-Class Centrally Acting Aminopeptidase Inhibitor
2.20	on Resistant Hypertension – Michel Azizi
3:30 p.m.	Kidney Denervation for Hypertension: Where We Are Now – Raymond Townsend
What Can Ger	nomic Sequencing Offer People with CKD?W240
Moderators: El	hussein Elhassan, Mathieu Lemaire
2:00 p.m.	Genomic Sequencing for Patients with Kidney Failure: What Is the Diagnostic Yield? – Jan Halbritter
2:30 p.m.	Exploring the Impact of Genomic Sequencing for Patients with Established CKD – Ali Gharavi
3:00 p.m.	Health Economic Argument for Early Genomic Sequencing for Patients with
•	CKD – Paola Romagnani
3:30 p.m.	Diagnostic Yield and Clinical Utility of Genomic Sequencing for Children with
•	CKD Ashasta Gunta

## Thursday, November 3, 2:00 p.m. – 4:00 p.m.

Future Shock: Transformational Therapies for Kidney FailureWF3 Tangerine Support is provided by an educational grant from eGenesis, Inc.		
	aymond Harris, Melissa West	
2:00 p.m.	Where Are We with Portable and Wearable Hemodialysis? –	
2.00 p.m.	Jonathan Himmelfarb	
2:30 p.m.	Progress Toward Implantable Artificial Kidneys – Shuvo Roy	
3:00 p.m.	Cure Is the Best Treatment: Genome Editing – Jeremy Duffield	
3:30 p.m.	Making Sure the Patient Perspective Is Heard: The Kidney Health Initiative	
3.30 p.m.	Patient and Family Partnership Council – Leigh-Ann Williams	
	•	
<b>New Direction</b>	s and Strategies to Improve Hypertension and	
Pain Manager	nent in CKDW415 Valencia	
Moderators: Li	nda Awdishu, Adriana Hung	
2:00 p.m.	It's in the Genes: The Knowns and Unknowns of Hypertension and CKD	
	Progression in African American Patients – Carol Horowitz	
2:30 p.m.	Implementation of a Genomics Program to Guide Optimal Selection of	
	Antihypertensive Medications – Rhonda Cooper-DeHoff	
3:00 p.m.	Get Smart: Using Pharmacogenomics in CKD Hypertension Management –	
	Michael Eadon	
3:30 p.m.	Improving Effectiveness and Safety of Opioid Use Through Pharmacogenomics	
	Guided Therapy – D. Max Smith	
Choose Your	Own Adventure: Nephrology Career PathsW314	
	anley Crittenden, Tejas Desai	
2:00 p.m.	The Research Nephrologist – Opeyemi Olabisi	
2:10 p.m.	The Private Practitioner – Timothy Pflederer	
2:20 p.m.	The Clinician Educator – Kenar Jhaveri	
2:30 p.m.	The Nephrologist Business Leader – Mahesh Krishnan	
2:40 p.m.	The Nephrologist in Industry – Yasmin Brahmbhatt	
2:50 p.m.	The Nephrologist in Government – Susan Mendley	
3:00 p.m.	Panel Discussion	
	Thursday, November 3, 4:30 p.m. – 6:00 p.m.	
Autonomol De	minora Tubulaina matatal Midney Bissass	
	ominant Tubulointerstitial Kidney Disease:	
	ics and TherapiesWF1 Tangerine	
	nthony Bleyer, Ronak Lakhia	
4:30 p.m.	Landscape of REN Mutations – Martina Zivna	
4:50 p.m.	UMOD Disease Genetics and Models – Luca Rampoldi	
5:10 p.m.	MUC1 Biology and Models – Anna Greka	
5:30 p.m.	Kidney Plasticity Revealed Through Reversal of PKD in Mice – Stefan Somlo	
Impact of Mic	roRNAs and Circular RNAs on the Pathogenesis and Prognosis of	
Glomerular Di	seasesW304	
Support is prov	ided by an educational grant from Travere Therapeutics, Inc.	
Moderators: Vi	neet Gupta, Francesco Schena	
4:30 p.m.	MicroRNAs in Membranous Nephropathy and FSGS – Mario Schiffer	
4:50 p.m.	MicroRNAs in IgA Nephropathy – Izabella Pawluczyk	
5:10 p.m.	MicroRNAs in Diabetic Nephropathy – Maurice Fluitt	
5:30 p.m.	Circular RNAs and MicroRNAs in Lupus Nephritis – Jeffrey Kopp	

### Thursday, November 3, 4:30 p.m. – 6:00 p.m.

	ng the Race-Free eGFR Equations in Clinical Practice:
	We Now?WF2 Tangerine
Support is pr	ovided by an educational grant from Chinook Therapeutics, Inc.
Moderators:	Cynthia Delgado, Neil Powe
4:30 p.m.	Adoption of the Race-Free Equations: Where Are We Now? – Joseph Vassalotti
4:50 p.m.	New Approaches to Medication-Related Decision Making After Taskforce Recommendations – Thomas Nolin
5:10 p.m.	Effect of 2022 CKD-EPI Equation on Donor Evaluation and Kidney Transplant Candidacy – John Friedewald
5:30 p.m.	Cystatin C Barriers and Facilitators to Widespread Implementation in Practice – Amy Karger
, ,	afts Fail: Clinical, Histopathological, and Molecular Approach to Chronic jury, Including the Barbara T. Murphy Endowed LectureshipWF3 Tangerine
ASN grateful	ly acknowledges Verici Dx, Renalytix, and the American Society of Transplantation for
supporting th	nis lectureship.
Moderators:	Roy Bloom, Mark Haas
4:30 p.m.	Improving Kidney Graft Long-Term Outcomes: Lessons Learned and New Perspectives: The Barbara T. Murphy, MB BAO BCh, Endowed Lectureship – Roslyn Mannon
4:50 p.m.	Molecular Approaches to Chronic Allograft Injury – Valeria Mas
5:10 p.m.	Update to Banff Histopathological Diagnosis of Chronic Allograft Injury – Michael Mengel
5:30 p.m.	Contributions of Antibody-Mediated and Cell-Mediated Alloimmunity to
·	Chronic Graft Injury – Peter Nickerson
European N	ephrology Highlights: Updates from the 2022 ERA CongressW224
ASN thanks t	the European Renal Association (ERA) for assistance with this session.
Moderators:	Serhan Tuglular, Christoph Wanner
4:30 p.m.	Basic Science and Translational Nephrology – Marianne Verhaar
4:50 p.m.	Epidemiology and Clinical Nephrology – Kitty Jager
5:10 p.m.	ESKD and Dialysis – Giovanni Gambaro
5:30 p.m.	Kidney Transplantation – Andreas Kronbichler

#### Thursday, November 3, 4:30 p.m. - 6:00 p.m.

	Oral Abstract Sessions
	h: Prediction, Diagnosis, RecoveryW230
	Katja Gist, Sarah Huen
4:30 p.m.	TH-OR01 Clonal Hematopoiesis of Indeterminate Potential Is Associated With a
	Higher Risk of Incident AKI – Caitlyn Vlasschaert
4:39 p.m.	TH-OR02 Leveraging AKI Recovery Patterns Reveals a Genome-Wide Significant
	Variant Associated With a Higher Risk of Non-Resolving AKI – Pavan Bhatraju
4:48 p.m.	TH-OR03 Associations of Blood Mitochondrial DNA Copy Number With Risk of AKI
	After Cardiac Surgery – Vasantha Jotwani
4:57 p.m.	TH-OR04 Oral Anticoagulant Therapy and Risk of Kidney Disease: A Nationwide
	Cohort Study – Ane Emilie Vestergaard
5:06 p.m.	TH-OR05 Urine NGAL for AKI Screening Following Triggering of Baby NINJA
	(Nephrotoxic Injury Negated by Just-in-Time Action) – Cara Slagle
5:15 p.m.	TH-OR06 Development of a Machine Learning Algorithm to Predict Major Adverse
	Kidney Events (MAKE) After Hospitalization – Jay Koyner
5:24 p.m.	TH-OR07 Machine Learning Models Uncover Subphenotypes of AKI With Unique
	Signatures That Associate With Differing Clinical Outcomes – George Vasquez-Rios
5:33 p.m.	TH-OR08 Machine Learning for Development of a Real Time AKI Risk Prediction
	Model in ICU With External Validation and Federated Learning at Five Medical
	Centers: From Model Development to Clinical Application – Chun-Te Huang
5:42 p.m.	TH-OR09 AKI Flagger: A Standardized AKI Definition Tool for Electronic Health
	Record (EHR) Research – Abinet Aklilu
5:51 p.m.	TH-OR10 Novel Urinary Proteins Differentiate Sub-Phenotypes in Patients With
	Sepsis-Induced AKI – Ian Stanaway
D. I	
	ient-Centered Interventions and OutcomesW414
	Sahir Kalim, Mariana Murea
4:30 p.m.	TH-OR11 Role of the Pre-Hemodialysis Lung Ultrasound for Dry-Weight Assessment
	and Intradialytic Hypotension Risk Prediction – Giulia Palazzini
4:39 p.m.	TH-OR12 Application of Intradialytic Magnetic Resonance Imaging and Spectroscopy
	Demonstrates Hemodialysis-Related Acute Brain Injury – Dickson Wong
4:48 p.m.	TH-OR13 Intradialytic Exercise Is Associated With Lower Mortality Risk in
	Hemodialysis Patients – Pedro Martins
4:57 p.m.	TH-OR14 0.075% Capsaicin Lotion for the Treatment of Peripheral Neuropathy in
	ESRD Patients: A Multicenter Randomized Double-Blind Placebo-Controlled, Cross-
	Over Trial – Parinada Kittidanairuk
5:06 p.m.	TH-OR15 Preferences for End-of-Life Care Among Dialysis Patients: A Discrete Choice
	Experiment – Ania Filus
5:15 p.m.	TH-OR16 DIALIZE China: A Phase 3b Study to Reduce Pre-Dialysis Hyperkalemia With
	Sodium Zirconium Cyclosilicate in Chinese Subjects – June Zhao
5:24 p.m.	TH-OR17 Effect of ESRD Treatment Choices (ETC) on Home Dialysis Utilization
	Among Incident Dialysis Patients - Kirsten Johansen

TH-OR18 The Effects of Implementing a Home Dialysis Project ECHO -

TH-OR19 High-Flow Arteriovenous Fistula and Myocardial Fibrosis in Hemodialysis

**Patients With Non-Contrast Cardiac Magnetic Resonance Imaging** – Jwa-kyung Kim <u>TH-OR20</u> **Biofunctionalized Vascular Access Graft Enhanced Patency and** 

Endothelialization in a Pig Arteriovenous (AV) Model – Prakash Parthiban Selvakumar

5:33 p.m.

5:42 p.m.

5:51 p.m.

Christopher Chan

## Thursday, November 3, 4:30 p.m. – 6:00 p.m.

Hypertension	and CVD: Epidemiology, Risk Factors, PreventionW240
Moderators: R	uth Dubin, Sandra Taler
4:30 p.m.	TH-OR21 Hyperaldosteronism Screening Among a Large Diverse Resistant
	Hypertension Population Within an Integrated Healthcare System – Victor Kim
4:39 p.m.	TH-OR23 Influence of Baseline Diastolic BP (DBP) on the Effects of BP Lowering on
	Cardiovascular (CV) Outcomes: A Meta-Analysis of NIH BP Trials – Amara Sarwal
4:48 p.m.	TH-OR24 Sex Difference in Cardiovascular Risk in Non-CKD and CKD: NHANES
·	1999-2018 – Ester Oh
4:57 p.m.	TH-OR25 Associations of Impaired Kidney Function With Cerebral Small Vessel
	Disease and Cognitive Disorders: Findings From the Framingham Heart Study –
	Dearbhla Kelly
5:06 p.m.	TH-OR26 Nutritional Status and Cardiorenal Syndrome: Associations of Protein-
·	Energy Wasting and Abdominal Obesity With the Risk of Heart Failure in CKD –
	Tejita Agarwal
5:15 p.m.	TH-OR27 Role of Human T Cells in Hypertension and Hypertensive Organ Damage –
	Johannes Stegbauer
5:24 p.m.	Invited Lecture Undiagnosed Primary Hyperaldosteronism and Renal Implications –
	Gordon Williams
Pediatric Nep	phrology: From Bench to BedsideW307
Moderators: D	Petlef Bockenhauer, Michelle Rheault
4:30 p.m.	TH-OR28 HLA-DR/DQ Single Molecule Eplet Mismatch and Formation of De Novo
·	Donor-Specific Anti-HLA Antibodies After Kidney Transplantation in Children –
	Vaka Sigurjonsdottir
4:39 p.m.	TH-OR29 A Multi-Population Polygenic Risk Score for Pediatric Steroid Sensitive
·	Nephrotic Syndrome Is Correlated With Disease Age at Onset – China Nagano
4:48 p.m.	TH-OR30 Prevalence and Persistence of CKD and Hypertension 36 Months Post-
·	Cisplatin in Children – Kelly McMahon
4:57 p.m.	TH-OR31 Rapid Correction of Hypernatremia Is Not Associated With Mortality or
·	Neurological Morbidity in Children: The Correcting Hypernatremia in Children
	Study – Madeleine Didsbury
5:06 p.m.	TH-OR32 Intradialytic Hypotension and Mortality in Children and Young Adults –
	Xixi Zhao
5:15 p.m.	TH-OR33 Urinary DKK3 Predicts Short-Term eGFR Decline and Nephroprotective
	Efficacy of Antihypertensive Therapy in Children With CKD: Findings From the 4C
	Study and ESCAPE Trial – Franz Schaefer
5:24 p.m.	TH-OR34 Nedosiran in Patients With Primary Hyperoxaluria 1: Interim Results From
	an Extension Trial (PHYOX3) – John Lieske
5:33 p.m.	TH-OR35 Ciliary ARL13B Is a Major Driver of Kidney Cystogenesis – Robert Van Sciver
5:42 p.m.	TH-OR36 Arginine Metabolism Has a Pivotal Role in Cystogenesis of Tuberous
F - 7	Sclerosis Complex (TSC) and Its Inhibition Alleviates TSC Cyst Overload –
	Morris Nechama
5:51 p.m.	TH-OR37 Correction of Pkd1 Loss-of-Function Model by Targeted Therapeutic Gene
- 1- /	Transfer – Almira Kurbegovic

## Thursday, November 3, 4:30 p.m. – 6:00 p.m.

Technology-	Based Approaches in NephrologyW308
	Joseph Bonventre, Patrick Murray
4:30 p.m.	TH-OR38 Transdermal Glomerular Filtration Rate Measurement: Clinical Results From
4.50 p.m.	a Pilot Multicenter Study Establishing Feasibility and Efficacy – Richard Dorshow
4:39 p.m.	TH-OR39 Evaluation of Renal Blood Flow Using 64Cu-ATSM PET – Naoki Takahashi
4:48 p.m.	TH-OR40 Targeted Isolation of Urine-Derived Renal Tubular Cells for Personalised
4.40 p.111.	Medicine – Chutong Zhong
1:57 n m	TH-OR41 CODEX Multiplex Imaging Uncovers Unique Cell Types, States, and Niches in
4:57 p.m.	
F-06	Health and Disease – Daria Barwinska
5:06 p.m.	TH-OR42 Super-Resolution Microscopy in Clinical Specimens Using Conventional
F.15	Widefield Microscopes – Dominik Kylies
5:15 p.m.	TH-OR43 Analyzing Cell Type-Specific Dynamics of Metabolism in Kidney Repair
5.24	Ton Rabelink
5:24 p.m.	TH-OR44 High Resolution Spatially Resolved Transcriptomic Atlas of Kidney Injury and
	Repair With Direct RNA Hybridization-Based In Situ Sequencing – Haojia Wu
5:33 p.m.	TH-OR45 Genome-Wide CRISPR Screen Reveals That Elamipretide (SS-31) Mediated
	PLSCR3 Activation Mitigates Mitochondrial Dysfunction During AKI – Josie Silvaroli
5:42 p.m.	TH-OR46 Downregulation of Syndecan-1 and Alternative Complement in Renal
	Proximal Tubular Epithelial Cells by Crotamine/Sirna Complexes – Jacob van den Born
5:51 p.m.	TH-OR47 #AskRenal: Use of an Automated Twitter Account to Crowdsource
	Nephrology Queries – Jade Teakell
Transplantat	ion: Basic ResearchW314
	Xun-Rong Luo, Jonathan Maltzman
4:30 p.m.	TH-OR48 Using Three-Dimensional Imaging and Single-Cell Transcriptomics to
•	Interrogate Human Kidney Lymphatics in Transplant Rejection – Daniyal Jafree
4:39 p.m.	TH-OR49 Critical Role of CD74 in Immune Regulation and Allograft Tolerance –
	Zhabiz Solhjou
4:48 p.m.	TH-OR50 Single Nuclei RNA-Sequencing Identifies Distinct Immune Profiles in
•	Interstitial Fibrosis and Tubular Atrophy Human Allografts Following 15 Months
	Post-Transplantation – Thomas Rousselle
4:57 p.m.	TH-OR51 A Single-Nucleus RNA-Sequencing of Human Kidney Transplant Biopsies
•	Identifies a Novel Role of Pericytes and Endothelium in Cellular Rejection –
	Ahmad Halawi
5:06 p.m.	TH-OR52 IL-2/Anti-IL-2 Immune Complex Attenuates Cold Ischemia-Reperfusion
•	Injury in Kidney Transplantation by Expanding Regulatory T Cells – Ga Young Heo
5:15 p.m.	TH-OR53 Mobilizing MHC Class Ib-Restricted Regulatory CD8 T Cells (CD8 Treg) With
•	a Peptide Agonist Promotes Allograft Tolerance in a Fully Mismatched Mouse Kidney
	Transplant Model – John Choi
5:24 p.m.	TH-OR54 Targeting the Archetypal Innate Immune Receptor Integrin CD11b
•	Prolongs Kidney Allograft Survival in Nonhuman Primates (NHPs) – Abbas Dehnadi
5:33 p.m.	TH-OR55 Molecular and Cellular Mechanisms of Lipocalin-2-Mediated
•	Renoprotection in Kidney Transplantation – Anna Pfefferkorn
5:42 p.m.	TH-OR56 Phascolarctobacterium-Producing Propionate and Acute Rejection Among
•	Kidney Transplant Recipients – Hyunjeong Cho
5:51 p.m.	TH-OR57 Cytomegalovirus-Responsive CD4 T Cells Exhibit a Stable, Cytotoxic
•	Phenotype During the First Year After Solid Organ Transplant – Ayah Ahmad

# Poster Sessions Thursday, November 3 | West Exhibit Hall D

Poster Topics	Board #s
NIH/NIDDK and Informational Posters	INFO01-40
Educational Research	001–021
AKI: Biomarkers, Risk Factors, Treatments, Outcomes	022–081
AKI: Mechanisms - I	
CKD-MBD: Targets and Outcomes	142–176
Diabetic Kidney Disease: Basic - I	177–227
Diabetic Kidney Disease: Clinical - I	228–255
Vascular Access: From Biology to Managing Complications	256–303
Fluid, Electrolyte, and Acid-Base Disorders: Basic	304–354
Genetic Diseases of the Kidneys: Cystic - I	355–414
Glomerular Diseases: Inflammation and Fibrosis	415–439
Glomerular Diseases: Podocytopathies and Nephrotic Syndromes	440–471
Glomerular Diseases: Clinical, Outcomes, Trials - I	472–528
Pathology and Lab Medicine	529–588
Hypertension and CVD: Epidemiology, Risk Factors, Prevention	589–635
Transplantation: Basic	636–655
Anemia and Iron Metabolism	656–705
Diversity and Equity in Kidney Health - I	706–743
Sex and Reproductive Factors in Kidney Health	744–767
Voices, Choices, and Outcomes of Older Adults with CKD	768–799
Health Maintenance, Nutrition, Metabolism	800–851
CKD: Epidemiology, Risk Factors, Prevention - I	852-900
COVID-19: Long COVID	901–913
COVID-19: Vaccines and Outcomes ESRD/KTR	914–963
Late-Breaking Clinical Trials	964–996
NIDDK KUH Summer Undergraduate Research Program	997–1006

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.



# **Welcome Reception**

Thursday, November 3 6:00-7:00 p.m. West Exhibit Hall D

The Welcome Reception is supported by Fresenius Medical Care Renal Pharmaceuticals.



# DIGITAL PATHOLOGY ROOM Room W310

Pathology Room Hours

Thursday, Nov. 3 9:30 a.m. - 4:30 p.m.

Friday, Nov. 4 9:30 a.m. - 4:30 p.m.

You are invited to a hands-on review session of all the digital slides from the Renal Biopsy: Clinical Correlations session vignettes prior to Saturday, November 5, when the final diagnoses are discussed in depth and answers to the cases are distributed. Biopsy materials are available with renal pathologists onsite to direct your study of the cases and to provide individual instruction. There is no fee to visit the Pathology Room; however, space is limited and available on a first-come, first-served basis.

ASN thanks the Renal Pathology Society for assistance with the Digital Pathology Room.



## **ASN Career Fair**

Meet face-to-face with top employers looking to hire!

November 3–5 9:30 a.m. – 2:30 p.m.

#### **West Exhibit Hall D**



ASN invites you to take part in the ASN Career Fair. Connect with employers and find your next nephrology opportunity. All Annual Meeting registrants are welcome to participate for free!

Be on the lookout for the ASN Featured Employers Guide which will include open positions from top employers. It will be sent directly to your email after Kidney Week.

# Take charge of your career! Upload or update your resume on the ASN Career Center.





Get your resume in front of employers hiring nephrology professionals who search the database.



Search jobs that are posted right from your smartphone or tablet.



Be the first to get job alerts when a job that meets your criteria is posted.



Gain resume writing tips and how to prepare for an interview.

Visit **careers.asn-online.org** to get started!



# DAY-AT-A-GLANCE Friday, November 4

8:00 a.m. – 9:30 a.m.	
Plenary: ASN President's Medal, Barbara T. Murphy Trailblazer Award,	
John P. Peters Award, Donald W. Seldin Young Investigator Award and Address	c
State-of-the-Art Lecture	
State of the Art Eccture	
9:30 a.m. – 2:30 p.m.	
Morning Break (9:30 a.m. – 10:00 a.m.)	. West Exhibit Hall D
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)	West Exhibit Hall D
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)	
10:30 a.m. – 12:30 p.m.	
Basic/Clinical Science Sessions	
Developing Personalized Medicine for Peritoneal Dialysis Patients	WF2 Tangerine
Hypertension Is an Immune-Mediated Disease	
Nephron Endowment and Links to Cessation of Nephrogenesis	
New Insights into Paracellular Transport and Tight Junction Architecture in Kidney	VVZ40
	/VV∠3U
Regulatory, Inflammatory B Cells and Autoantibodies:	14/52 T
From Bench to Human Translation	WF3 Tangerine
Clinical Practice Sessions	
Nephrologists as Primary Care Physicians	WF1 Tangerine
Potpourri of Infection-Related Glomerular Diseases	
Update on Treatment Considerations in Nephrolithiasis	
opuate on Treatment Considerations in Nephronthiasis	VV-1-
Translational Sessions	
Biomarkers and Diabetic Kidney Disease	W224
Throw It into Reverse: AKI Science at the Bedside	
Oral Abstract Session	
High-Impact Clinical Trials	W415 Valencia
Other Event	
Fellows-in-Training Bowl: Semi-Finals and Finals	West Evhibit Hall D
Tellows III Training bowl. Seriii Tiliais and Tiliais	West Exhibit Hall D
12:45 p.m. – 1:45 p.m.	
<b>Educational Symposia (Hyatt Regency Orlando)</b> – Doors open at 12:30 p.m.	
Current and Future Approaches to the Diagnostic Assessment and	
Management of AKI in Patients with Cirrhosis	. Regency Ballroom R
Hyperphosphatemia Management in Adults Treated with Dialysis for	
Kidney Failure: Old Lessons, New Directions	Regency Ballroom S
Update on the Management of Recurrent Hyperkalemia Associated with	
RAAS Inhibitors in Patients with CKD and ESRD	Regency Ballroom T
2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
Best of ASN Journals 2022: JASN, CJASN, and Kidney360	W314
Emerging Therapeutic Approaches in AKI: New Targets and How to Reach Them	
Extracellular Matrix Pathobiology in CKD and Alport Syndrome	
Lifestyle Interventions: Findings from Recent Trials	
Macula Densa Front and Center	
Novel Mechanisms of BP Regulation	
Pediatric AKI Is More Than Just a (Creatinine) Number: Challenges and Advances to	.o care w240

2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions (cont.) Regenerating the Diabetic Kidney	14/224
Vascular Access: Promising Dialysis Innovation to Ensure Equity in Opportunities and	VVZZ4
Care DeliveryWF2	Tangerine
Care Deliverywirz	. rangemie
Clinical Practice Sessions	
Evidence-Based Management of Septic AKI,	
Including the Burton D. Rose Endowed Lectureship	W307
Glomerulonephritis in Systemic Diseases: Emphasis on Emerging Therapies and	
PrognosisW41	15 Valencia
Improving Patient Care at the Transition to Kidney Failure:	
Insights from USRDS and DOPPSW3	320 Chapin
Translational Sessions	
Modern Scientific Breakthroughs: Are COVID-19 Vaccines Enough for	
Kidney Transplant Recipients?WF3	R Tangerine
Molecular Diagnostics in Interpretation of Native and Transplant Kidney Biopsies	_
Novel Strategies for Preventing End-Organ Damage and Dysfunction from CKD-MBD,	
Including the Jack W. Coburn Endowed Lectureship	W414
4:00 p.m. – 4:30 p.m.	
Afternoon BreakWest Lobby D, West Lobby E/F, W415 Valencia Foyer, W	V320 Foyer
4:30 p.m. – 6:00 p.m.	
Basic/Clinical Science Session	
	l Tangerine
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	l Tangerine
	l Tangerine
Where It Begins: Complex Genetic Drivers of Kidney PhenotypesWF1  Clinical Practice Sessions  AKI in Cirrhosis: Will Personalized Management Improve Outcomes?	W224
Where It Begins: Complex Genetic Drivers of Kidney PhenotypesWF1  Clinical Practice Sessions  AKI in Cirrhosis: Will Personalized Management Improve Outcomes?  Leveraging Social Media to Create, Learn, Teach, Advocate, and Dispel Misinformation	W224
Where It Begins: Complex Genetic Drivers of Kidney PhenotypesWF1  Clinical Practice Sessions  AKI in Cirrhosis: Will Personalized Management Improve Outcomes?  Leveraging Social Media to Create, Learn, Teach, Advocate, and Dispel Misinformation  Trauma Behind My Smile: Better Access to Behavioral Health Resources During the	
Where It Begins: Complex Genetic Drivers of Kidney PhenotypesWF1  Clinical Practice Sessions  AKI in Cirrhosis: Will Personalized Management Improve Outcomes?  Leveraging Social Media to Create, Learn, Teach, Advocate, and Dispel Misinformation	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	W224 W304 B Tangerine P Tangerine W314 W230 W307 W240 W308 W414
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	W224 W304 B Tangerine P Tangerine W314 W230 W307 W240 W308 W414
Where It Begins: Complex Genetic Drivers of Kidney Phenotypes	

Download the meeting app or scan the QR code for more details and updates.



#### Friday, November 4, 8:00 a.m. – 9:30 a.m.

State-of-the-Art Lecture......W415 Valencia

ASN President's Medal – Patrick Gee, Glenda Roberts, David Rush

Plenary: ASN President's Medal, Barbara T. Murphy Trailblazer Award, John P. Peters Award, Donald W. Seldin Young Investigator Award and Address,

8:00 a.m.

8:10 a.m.	Barbara T. Murphy Trailblazer Award – Julie Ingelfinger
8:20 a.m.	John P. Peters Award – Sharon Anderson
8:30 a.m.	Donald W. Seldin Young Investigator Award and Address "Unexpected Roles
	for Renal Olfactory Receptors" – Jennifer Pluznick
9:00 a.m.	State-of-the-Art Lecture "Making the Impossible Possible: First-In-Human
	Clinical Grade Kidney Xenotransplant" – Jayme Locke
	Friday, November 4, 10:30 a.m. – 12:30 p.m.
Developing I	Personalized Medicine for Peritoneal Dialysis PatientsWF2 Tangerine
Moderators: J	effrey Perl, Isaac Teitelbaum
10:30 a.m.	Developing Personalized Medicine for Dialysis Patients – Rajnish Mehrotra
11:00 a.m.	Genetic Studies and Precision Medicine in Dialysis Patients – Olivier Devuyst
11:30 a.m.	Individualizing Dialysis Therapy: Identifying the Patient at Risk – Claus Peter Schmitt
12:00 p.m.	Cytoprotection in Peritoneal Dialysis – Rebecca Herzog
	n Is an Immune-Mediated DiseaseW311
	Susan Gurley, Jennifer Pluznick
10:30 a.m.	Is Hypertension an Immune Disease? – David Harrison
11:00 a.m.	Monocytes as Immune Targets in Arterial Hypertension – Philip Wenzel
11:30 a.m.	Minocycline as a Treatment of Resistant Hypertension: Results of a Clinical Study – Eileen Handberg
12:00 p.m.	Role of Immune Cells in Hypertension – Ernesto Schiffrin
Nephron End	dowment and Links to Cessation of NephrogenesisW240
Moderators: J	ennifer Charlton, Greg Dressler
10:30 a.m.	Progenitor Translatome Changes End Nephrogenesis – Raphael Kopan
11:00 a.m.	Prolongation of Mammalian Nephrogenesis by Excess Fetal Glial Cell Line- Derived Neurotrophic Factor – Satu Kuure
11:30 a.m.	Lin28 and Let-7 Regulate Cessation of Murine Nephrogenesis – Jihan Osborne
12:00 p.m.	Chromatin Changes in Nephron Progenitors – Samir El-Dahr
	into Paracellular Transport and Tight Junction Architecture in KidneyW230
Moderators: \	/ivek Bhalla, Alan Yu
10:30 a.m.	Claudin-2 and -12 Form Independent Complementary Pores Required to Maintain Calcium Homeostasis – R. Todd Alexander
11:00 a.m.	Interaction Between Epithelial Sodium Channel (ENaC) and Claudin-8 Modulates Paracellular Permeability in Collecting Duct – Ali Sassi
11:30 a.m.	Calcium Sensing and Claudin Regulation in Kidney – Henrik Dimke
12:00 p.m.	Role of Claudin-10 Splice Variants in Paracellular Transport in Kidney and Underlying HELIX Syndrome – Dorothee Günzel

### Friday, November 4, 10:30 a.m. – 12:30 p.m.

	Inflammatory B Cells and Autoantibodies: From Bench to
	slationWF3 Tangerine Mohammed Javeed Ansari. Paolo Cravedi
10:30 a.m.	Development of Antigen-Specific Memory B Cells During Alloimmunity –
11:00 a.m.	Stanley Jordan
11.00 a.m.	B Cell Cytokine Balance Early Post-Transplantation Is a Predictive Biomarker for
11:30 a.m.	Post-Transplant Outcomes – Aravind Cherukuri
11.30 a.111.	Human Bregs Expressing TIM-1 and TIGIT Exhibit Regulatory Activity That Correlates with Kidney Transplant Outcomes – SangKon Oh
12:00 p.m.	Autoantibodies Contribute to Microvascular Rarefaction and Progressive
12.00 p.111.	Kidney Dysfunction – Marie-Josee Hebert
	Riuney Dysiunction - Marie 303ee Flebert
Nephrologis	ts as Primary Care PhysiciansWF1 Tangerine
	Jeffrey Berns, Mallika Mendu
10:30 a.m.	Lipid Management in Patients with Kidney Diseases – Roy Mathew
11:00 a.m.	Immunization in CKD – Snigdha Reddy
11:30 a.m.	Cancer Screening in Dialysis Patients – Mitchell Rosner
12:00 p.m.	Approach to Depression Screening and Treatment in Kidney Diseases –
	Susan Hedayati
Potpourri of	Infection-Related Glomerular DiseasesW304
	ovided by an educational grant from Travere Therapeutics, Inc.
	Ali Poyan-Mehr, Anjali Satoskar
10:30 a.m.	Epidemiology, Bacteriology, and Patterns of Glomerular Injury in Bacterial
	Infection-Related Glomerulonephritis – Joseph Gaut
11:00 a.m.	Clinical Manifestations, Management, and Outcomes of Bacterial Infection-
	Related Glomerulonephritis – Samir Parikh
11:30 a.m.	Viral-Associated Glomerular Diseases: Patterns of Glomerular Injury and
	Pathogenesis – Christina Wyatt
12:00 p.m.	Clinical Manifestations and Management of Viral-Associated Glomerular
'	Diseases – Meghan Sise
Update on T	reatment Considerations in NephrolithiasisW414
•	Cynthia Denu-Ciocca, Andrew Schwaderer
10:30 a.m.	Using Next Generation Sequencing to Identify Monogenic Urinary Stone
	Disease Patients – Peter Harris
11:00 a.m.	Dietary Modification to Prevent Stone Recurrence: Does It Work? –
	Megan Prochaska
11:30 a.m.	Clinical Pearls for the Use of 24-Hour Urine Studies to Assess Stone Risk –
	John Asplin
12:00 p.m.	Oxalate and Adverse Health Effects: More Than Just Stones? – Felix Knauf
Riomarkers	and Diabetic Kidney DiseaseW224
	Steven Coca, Wenjun Ju
10:30 a.m.	Albuminuria and GFR – Hiddo Heerspink
10.30 a.m.	Circulating Protein Markers – Monika Niewczas
11:30 a.m.	Epigenetic Markers – Assam El-Osta
12:00 n m	Machine Learning – Laura Mariani

## Friday, November 4, 10:30 a.m. – 12:30 p.m.

Throw It into	o Reverse: AKI Science at the BedsideW320 Chapin
	Eryn Dixon, Joachim Ix
10:30 a.m.	Updates from the Kidney Precision Medicine Project – Jonathan Himmelfarb
11:00 a.m.	Mechanistic Markers Have Transformed Oncology, So What's on the Horizon
	for AKI? – Shruti Gupta
11:30 a.m.	SGLT2 Inhibitors and AKI Protection: Signal, Noise, So What? – Sarah Huen
12:00 p.m.	Advances in Imaging to Assess Kidney Health and Reserve – Anand Srivastava
High-Impact	Clinical TrialsW415 Valencia
Please check	the Kidney Week app or the ASN webiste for session details.
Falleure in T	raining Bowl: Semi-Finals and Finals
	ovided by Chinook Therapeutics, Inc.
1.1	ving education credits are not being offered for this activity.
Note. Comuni	ung education credits are not being offered for this activity.
	Friday, November 4, 12:45 p.m. – 1:45 p.m.
E	iducational Symposia (Hyatt Regency Orlando) – Doors open at 12:30 p.m.
Lunch is pr	ovided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.
	Future Approaches to the Diagnostic Assessment and
	t of AKI in Patients with CirrhosisRegency Ballroom R
	ovided by an educational grant from Mallinckrodt Pharmaceuticals.
12:45 p.m.	Introduction – Kathleen Liu (Moderator)
12:55 p.m.	Current Approach to the Diagnostic Evaluation of Patients with AKI and Cirrhosis – Chirag Parikh
1:15 p.m.	Evidence-Based Management of Hepatorenal Syndrome with AKI –
•	Florence Wong
1:35 p.m.	Questions and Answers
Hyperphosp	hatemia Management in Adults Treated with Dialysis for
	re: Old Lessons, New Directions
•	ovided by an educational grant from Akebia Therapeutics, Inc.
12:45 p.m.	Introduction – Ebele Umeukeje (Moderator)
12:55 p.m.	Phosphorus Metabolism in Kidney Failure: How Biology Informs Medication
'	Therapy – Sagar Nigwekar
1:15 p.m.	Diet Strategies to Improve Hyperphosphatemia Independent of and Integrated
,	with Medication Therapy – Kathleen Hill Gallant
1:35 p.m.	Questions and Answers
Hardete en Al	Management of December 11 months leaves Associated with
Update on ti	ne Management of Recurrent Hyperkalemia Associated with tors in Patients with CKD and ESRDT Regency Ballroom T
	ovided by an educational grant from CSL Vifor.
12:45 p.m.	Introduction: Rationale Behind Using RAAS Inhibitors in Patients with CKD and
12.43 p.111.	CVD – Alan Pao (Moderator)
12:55 p.m.	Advances in Therapies for Recurrent Hyperkalemia in Patients with CKD and
12.33 p.111.	ESRD – Charles Wingo
1:15 p.m.	Update on Potassium Balance and the Molecular Mechanism Underlying
5 p	Hyperkalemia – Chou-Long Huang
1.25	Overtiens and American

1:35 p.m.

Questions and Answers

<b>Best of ASN</b>	Journals 2022: JASN, CJASN, and Kidney360W314
ASN thanks J.	ASN, CJASN, and Kidney360 for assistance with this session.
Moderators:	Michael Allon, Mark Knepper, Rajnish Mehrotra
2:00 p.m.	Advances in Glomerular Disease – Katalin Susztak
2:40 p.m.	Caring for Patients with Kidney Failure – Dana Miskulin
3:20 p.m.	New Insights into Hypertension and CVD – Steven Crowley
Emerging Th	nerapeutic Approaches in AKI: New Targets and How to Reach ThemW308
Moderators:	Monica Chang Panesso, Prabhleen Singh
2:00 p.m.	Senolytic Treatment to Promote Kidney Repair – David Ferenbach
2:30 p.m.	Mitochondrial Therapy for AKI – Amandeep Bajwa
3:00 p.m.	Nanotherapeutics in Kidney Biology – Eun ji Chung
3:30 p.m.	Clinical Potential of Nanoparticles in AKI – Daniel Heller
	Matrix Pathobiology in CKD and Alport SyndromeWF1 Tangerine
Moderators:	Tomoko Horinouchi, Roser Torra
2:00 p.m.	Update on the Alport Syndrome Community, Research, and Education Efforts –
2.20	B. Andre Weinstock
2:30 p.m.	Kidney Basement Membrane Composition, Regulators, and Human Disease Associations – Rachel Lennon
3:00 p.m.	Developing Gene Editing Approaches in Alport Syndrome – Jeffrey Miner
3:30 p.m.	Therapeutic Development in Alport Syndrome – Oliver Gross
Lifestyle Into	erventions: Findings from Recent TrialsW304
	Devika Nair, Daniel Weiner
2:00 p.m.	Mobilizing a Multidisciplinary Team to Conduct a Lifestyle Intervention in
2.20	Patients with CKD – Erin Howden
2:30 p.m.	Sit Less, Move More! Targeting Sedentary Behavior in Patients with CKD – Srinivasan Beddhu
3:00 p.m.	Exercise to Improve Outcomes in CKD: Evidence for Benefit? – Thomas Wilkinson
3:30 p.m.	Barriers and Facilitators to Adopting Lifestyle Interventions: A Patient's
	Perspective – Curtis Warfield
	sa Front and CenterW230
Moderators:	Branko Braam, Clintoria Williams
2:00 p.m.	Macula Densa Cells and Tubuloglomerular Feedback: The Basics – Scott Thomson
2:30 p.m.	Unique Gene Expression Profile of Macula Densa Cells – Lihe Chen
3:00 p.m.	Novel Macula Densa SGLT1-NOS1 Signaling Pathway and Its Implications –
·	Jie Zhang
3:30 p.m.	New Features of Macula Densa Cells: From Maculapodia to Protein Synthesis
•	Powerhouse – Janos Peti-Peterdi

	nisms of BP RegulationW311
	eyona King, Aaron Polichnowski
2:00 p.m.	Roles of WNK4 and SPAK in Potassium-Mediated Dephosphorylation of the NaCl Cotransporter – David Ellison
2.20 n m	•
2:30 p.m.	Hypothalamic Control of Sympathetic Nerve Activity in Hypertension – Sean Stocker
3:00 p.m.	Mechanisms by Which Fructose Influences BP – Richard Johnson
3:30 p.m.	Elucidating Immune Mechanisms Causing Hypertension During Pregnancy –
3.30 p.iii.	Kedra Wallace
Pediatric AKI	Is More Than Just a (Creatinine) Number:
Challenges ar	nd Advances to CareW240
Moderators: T	ahagod Mohamed, Rupesh Raina
2:00 p.m.	Pediatric AKI: Another Example of How Children Are Not Little Adults – Jeffrey Fadrowski
2:30 p.m.	Advances in the Prevention and Identification of Early AKI: The Role of
	Biomarkers and Artificial Intelligence – Shina Menon
3:00 p.m.	Role and Impact of Quality Improvement Initiatives in Pediatric AKI – Stuart Goldstein
3:30 p.m.	Kidney Prognosis of Children with AKI – Cherry Mammen
Regenerating	the Diabetic KidneyW224
Moderators: S	haron Adler, Matthias Kretzler
2:00 p.m.	Kidney Organoids for Disease Modeling – Nuria Montserrat
2:30 p.m.	Immunomodulation versus Direct Repair – Lilach Lerman
3:00 p.m.	Organoid Models for Studying Diabetic Nephropathy: Promises and
	Challenges – Yun Xia
3:30 p.m.	Mitochondrial Transfer – Kei Fukami
	ess: Promising Dialysis Innovation to Ensure Equity in
Opportunities	s and Care DeliveryWF2 Tangerine
Moderators: A	nna Burgner, Monnie Wasse
2:00 p.m.	Journey of Hemodialysis Access: The Patient Perspective – Caroline Wilkie
2:30 p.m.	Cells to Polytetrafluoroethylene: How Biology Leads Us to New Technology in
	Vascular Access – Laisel Martinez
3:00 p.m.	Visualizing Hemodialysis Vascular Access: Updates and Refreshers in Lessons
	from Radiology – Dheeraj Rajan
3:30 p.m.	Shared Decision Making in Vascular Access: Practices to Achieve Equity and Personalized Care – Louise Moist

Evidence-Ba	sed Management of Septic AKI,
	e Burton D. Rose Endowed LectureshipW307
ASN grateful	ly acknowledges Wolters Kluwer (publisher of UpToDate), the Beth Israel Deaconess
Medical Cent	er Department of Medicine Foundation, the Rose Family, and several of Dr. Rose's
colleagues fo	r supporting this lectureship.
Moderators:	Jay Koyner, Blaithin McMahon
2:00 p.m.	Fluid Management in Septic AKI: When, What Type, and How Much?
	The Burton D. Rose, MD, Endowed Lectureship – Kathleen Liu
2:30 p.m.	Vasoactive Drugs in Septic Shock and AKI: Which Drugs to Use, and Which
	Parameters to Target? – Lui Forni
3:00 p.m.	Corticosteroid Therapy in Sepsis: Current Recommendations –
	Marlies Ostermann
3:30 p.m.	RRT in Septic AKI: When to Start, How to Dose, and When to Stop? – Ron Wald
Glomerulon	ephritis in Systemic Diseases:
<b>Emphasis or</b>	n Emerging Therapies and PrognosisW415 Valencia
Support is pro	ovided by an educational grant from Travere Therapeutics, Inc.
Moderators:	Isabelle Ayoub, Dana Rizk
2:00 p.m.	IgA Vasculitis Nephritis: New Insights into Prognosis and Treatment from a
	Large International Study – Evangeline Pillebout
2:30 p.m.	Pathogenesis-Based Treatment Approaches to ANCA Glomerulonephritis and
	Vasculitis – David Jayne
3:00 p.m.	Current Treatment of Cryoglobulinemic Glomerulonephritis and Vasculitis –
	David Saadoun
3:30 p.m.	Treatment of Lupus Nephritis: Beyond the Usual Suspects – Liz Lightstone
Improving F	Patient Care at the Transition to Kidney Failure:
Insights froi	m USRDS and DOPPSW320 Chapin
Moderators:	Elaine Ku, Sri Lekha Tummalapalli
2:00 p.m.	Initiation of Treatment for Kidney Failure: How COVID-19 Has Influenced Care
	Practices in the United States – James Wetmore
2:30 p.m.	International Perspective: Optimal Preparation for Kidney Failure –
	Roberto Pecoits-Filho
3:00 p.m.	United States Perspective: What Is the "Optimal Start" for Kidney Replacement
	Therapy? How Often Do We Achieve It? – Kirsten Johansen
3:30 p.m.	Aligning Care to Improve Management of CKD Complications: From Before to
	After the Transition to Dialysis – Christian Combe
	entific Breakthroughs: Are COVID-19 Vaccines Enough for
Kidney Tran	splant Recipients?WF3 Tangerine
	Dianne McKay, Miklos Molnar
2:00 p.m.	COVID-19: Tweaking Immune Responses – Maricar Malinis
2:30 p.m.	COVID-19: What We Know About Humoral and Cellular Responses? –
	Paolo Cravedi
3:00 p.m.	Immune Responses in Transplant Recipients Who Received a Third Dose of
	mRNA-1273 – Atul Humar
2.20 n m	Vaccina Effectiveness in Transplant Posinients - Andrew Karaha

Molecular D	iagnostics in Interpretation of Native and Transplant Kidney BiopsiesW315
Support is pro	ovided by an educational grant from Travere Therapeutics, Inc.
Moderators:	Enver Akalin, Ivy Rosales
2:00 p.m.	Glomerular Transcriptomic Profiles in Nephrotic Syndrome – Jeffrey Hodgin
2:30 p.m.	Transcriptomic Studies in IgA Nephropathy and Lupus Nephritis –
	Francesco Schena
3:00 p.m.	Transcriptomics and the Pathogenesis of Diabetic Nephropathy –
	Raymond Harris
3:30 p.m.	Molecular Diagnostics of Kidney Transplant Rejection: An Update –
	Candice Roufosse
Novel Strate	gies for Preventing End-Organ Damage and Dysfunction from
	ncluding the Jack W. Coburn Endowed LectureshipW414
	ly acknowledges Amgen for support of the Jack W. Coburn, MD, Endowed Lectureship.
Moderators:	Valentin David, Jessica Kendrick
2:00 p.m.	A Tangled Web: Complex Relationship Between CKD-MBD, Inflammation, and
	Anemia – Jodie Babitt
2:30 p.m.	Contribution of Urinary Phosphate to CKD Progression – Kyle Jansson
3:00 p.m.	Novel Strategies for the Prevention of Vascular Calcification in CKD –
	Demetrios Braddock
3:30 p.m.	Systems Biology Approach to the Management of CKD-MBD:
	The Jack W. Coburn, MD, Endowed Lectureship – Eleanor Lederer
	Friday, November 4, 4:30 p.m. – 6:00 p.m.
Whose It Do	wines Compley Constite Drivers of Vidney Phonetimes
	gins: Complex Genetic Drivers of Kidney PhenotypesWF1 Tangerine Moumita Barua, Afshin Parsa
4:30 p.m.	GWAS Identify Risk Variants in Diabetic Nephropathy – Jose Florez
4:50 p.m.	GWAS-Defined Drug Targets in IgA Nephropathy – Krzysztof Kiryluk
4.30 p.m. 5:10 p.m.	Integrating Multiomics Data for a Better Understanding of Kidney Function and
3.10 p.111.	Disease – Anna Kottgen
E-20 n m	APOL1: Toward Precision Medicine Approaches – Adriana Hung
5:30 p.m.	APOLI: Toward Precision Medicine Approaches – Adriana Hung
	osis: Will Personalized Management Improve Outcomes?W224
	Jean Maxime Cote, Ashita Tolwani
4:30 p.m.	Pathogenesis of Hepatorenal Syndrome – Juan Carlos Velez
4:50 p.m.	Albumin Therapy in Cirrhosis: Too Much of a Good Thing? – Andrew Allegretti
5:10 p.m.	Vasoconstrictor Therapy in Hepatorenal Syndrome: What Is the Evidence? –
	Mitra Nadim
5:30 p.m.	AKI Biomarkers in Patients with Cirrhosis: Can Improved Phenotyping Guide
	Better Therapy? – Justin Belcher

	Social Media to Create, Learn, Teach, Advocate, and Dispel MisinformationW304 Bourne Auguste, Gates Colbert  Medical Illustrations and Visual Abstracts as a Means to Effectively  Communicate Science – Sophia Ambruso  Podcasts for Medical Education: Learning by Listening – Adam Rodman
5:20 p.m.	What Can a Nephrologist Do About Medical Misinformation? – Jen Gunter
Trauma Behi	nd My Smile: Better Access to Behavioral Health Resources During the
ASN gratefull	rocess, Including the Celeste Castillo Lee Endowed LectureshipWF3 Tangerine y acknowledges Travere Therapeutics and several of Celeste's family members, friends, and support of the Celeste Castillo Lee Endowed Lectureship.
Moderators: /	Anne Dawson, Martha Pavlakis
4:30 p.m.	Incorporating Mental Health Practices by Increasing Psychosocial Education for Kidney Recipients: The Celeste Castillo Lee Endowed Lectureship – Patrick Gee
4:50 p.m.	Impact of Having Access to Behavioral Health for Kidney Recipients – Nichole Jefferson
5:10 p.m.	Behavioral Challenges That May Arise and Adherence Before and After Kidney Transplantation – Jennifer Jones
5:30 p.m.	Goal-Directed Behavioral Health Tools and Lack of Access to Behavioral Health – Jennifer Steel
Advancing C	linical Trials for People with Kidney Diseases: An OverviewWF2 Tangerine
Moderators: I	ynee Galley, Amanda Grandinetti
4:30 p.m.	Primer on Conducting Clinical Trials – Aliza Thompson
4:50 p.m.	Patient Advisory Boards That Guide Design, Outreach, and Engagement for Your Clinical Trials – Glenda Roberts
5:10 p.m.	Developing Studies to Engage Diverse Communities Where They Are – Opeyemi Olabisi
5:30 p.m.	Conducting Clinical Trials for Innovative Therapeutics – Barbara Gillespie
Building Capacity to Collect Patient Preferences Information for	
Innovative K	idney DevicesW315

Note: Continuing education credits are not being offered for this activity.

#### **Oral Abstract Sessions**

Advances in I	Mineral Metabolism and NephrolithiasisV	N314
Moderators: R	losa Moyses, Anna Zisman	
4:30 p.m.	FR-OR01 The Effect of a Fermentable Dietary Fiber Inulin on a Rat Model of CKD-	
	MBD – Neal Chen	
4:39 p.m.	FR-OR02 Estrogen Protects Female Mice With CKD From Developing FGF23-Induce	∍d
	Left Ventricular Hypertrophy – Dominik Kentrup	
4:48 p.m.	FR-OR03 Vitamin D Receptor Regulates Furin-Mediated FGF23 Cleavage – Petra Sin	
4:57 p.m.	FR-OR04 Skeletal Muscle Is a Novel Source of FGF23 in Mouse Models of CKD and	
	Skeletal Muscle Atrophy – Kylie Heitman	
5:06 p.m.	FR-OR05 Parathyroidectomy Decreases Muscle Expression of TGF-β1 and Improve	S
	Muscle Function – Eduardo Duque	
5:15 p.m.	FR-OR06 Early Changes in Bone Turnover Markers Predict Bone Loss After Kidney	
	Transplantation – Hanne Joergensen	
5:24 p.m.	FR-OR07 Hepatocyte Nuclear Factor 4 Alpha 2 Is a Novel Osteoblast Transcription	
<b>5</b> 22	Factor That Plays a Role in CKD-MBD – Marta Martinez-Calle	
5:33 p.m.	FR-OR08 Encaleret Normalized Mineral Homeostasis in Autosomal Dominant	
5.40	Hypocalcemia Type 1 (ADH1) in a Phase 2 Study – Kelly Roszko	
5:42 p.m.	FR-OR09 A Spatially Anchored Transcriptomic Atlas of the Human Kidney Papilla	
	Identifies Significant Immune Injury and Matrix Remodeling in Stone Disease	
	Patients – Angela Sabo	
5:51 p.m.	FR-OR10 Crystalluria Impairs Macrophage Function During Kidney Stone Formatio	n –
	Tanecia Mitchell	
AKI Research	: MechanismsV	N230
	heng Dong, Leah Siskind	
4:30 p.m.	FR-OR11 Intracellular Magnesium Trafficking: A Novel Target to Prevent Ischemic	
p	Kidney Injury – William Reeves	
4:39 p.m.	FR-OR12 Proximal Tubule Pannexin 1 Channel Regulates Cell Death and	
p	Inflammation During AKI – Nabin Poudel	
4:48 p.m.	FR-OR13 Proteomic Analysis Reveals Proteins Associated Exclusively With Urinary	
o p	Muddy Brown Granular Casts – Michael Janech	
4:57 p.m.	FR-OR14 Ketone Body Metabolism in Renal Endothelium Triggers PPAR Signaling,	
	Reduces Immune Cell Recruitment, and Preserves Kidney Function Upon	
	Ischemia/Reperfusion Injury – Mila Borri	
5:06 p.m.	FR-OR15 Kidney Injury Molecule-1 (KIM-1) Shapes the Kidney Immune	
	Microenvironment via Lymphotoxin Beta Receptor (LTbR) Signaling –	
	Naoka Murakami	
5:15 p.m.	FR-OR16 Kidney Resident Macrophages Alter MHC II Expression and Location in	
	Response to Acute and Chronic Injury – Elise Erman	
5:24 p.m.	FR-OR17 Tubular Epithelium-Specific Deletion of Megalin Aggravates	
p	Ischemia/Reperfusion Kidney Injury and Accelerates the Progression to CKD –	
	Qingtian Li	
5:33 p.m.	FR-OR18 The Role of the Circadian Clock System in the Transition From AKI to CKI	<b>)</b> –
F	Yina Fang	
5:42 p.m.	FR-OR19 TIGIT Modulates Kidney T Cell Memory Phenotype and Metabolic Profile	
- / · =   F · · · · ·	and Mediates Both Ischemic and Nephrotoxic AKI in Mice – Sanjeev Noel	
5:51 p.m.	FR-OR20 Proximal Tubular Epithelial Cell States in KPMP Protocol Kidney Biopsies	
- F- /	Are Linked to Short Term AVI Patient Outcomes Jappifor Schaub	

CKD: Clinical	Outcomes, Trials, Mechanistic InsightsW30
Moderators:	Teresa Chen, James Wetmore
4:30 p.m.	FR-OR21 Air Pollution, Genetic Factors, and the Risk of Incident CKD: A Prospective
	Study of Polygenic Risk Score Analysis in the UK Biobank – Boram Weon
4:39 p.m.	FR-OR22 Time-Dependent Risk Differences in Kidney Failure and Death Between
	Black and White Veterans Following Incident CKD – Guofen Yan
4:48 p.m.	FR-OR23 Protein Carbamylation and the Risk of CKD Progression – Sahir Kalim
4:57 p.m.	FR-OR24 Changes in CKD Prevalence in the United States Using the Age-Adapted
	CKD Classification System – Maria Clarissa Tio
5:06 p.m.	FR-OR25 Dipstick Urinalysis Protein and Specific Gravity Can Identify Patients With
	Early CKD Who Lack a Quantified Proteinuria Measurement – Meredith McAdams
5:15 p.m.	FR-OR26 Dapagliflozin Effect on Hospital Admissions in Patients With CKD: A Post
	Hoc Analysis of the DAPA-CKD Trial – Meir Schechter
5:24 p.m.	FR-OR27 Notch Blockade Specifically in FSP-1-Positive Cells Ameliorates Renal
	Fibrosis by Attenuating Inflammation – Jizhong Cheng
5:33 p.m.	FR-OR28 Cyclin G1 Promotes Proximal Tubule Cell Maladaptive Dedifferentiation
	and Fibrosis in CKD – Bertha Elias
5:42 p.m.	FR-OR29 PRDM16 Protected Tubular Mitochondrial Function and Attenuated Renal
	Fibrosis by Upregulating PGC-1α – Qian Yuan
5:51 p.m.	FR-OR30 Unbiased Human and Mouse Kidney Metabolomics Identifies the Key Role
	of NAD Metabolism in Kidney Disease Development – Tomohito Doke
Diabetic Kid	ney Disease: From Single Cell to OutcomesW240
	John He, Karin Jandeleit-Dahm
4:30 p.m.	FR-OR31 The Single-Cell Landscape of Kidney Immune Cells Reveals Transcriptional
·	Heterogeneity in Late Diabetic Kidney Disease – Jia Fu
4:39 p.m.	FR-OR32 Human Kidney Multimodal Single Cell and Spatial Transcriptomics Atlas
	Identify Key Cell Types and Pathways for Diabetic Kidney Disease – Amin Abedini
4:48 p.m.	FR-OR33 Multi-Omic Analysis Identifies a New Class of Proximal Tubular Cell With
·	Metabolic Alterations in Diabetic Kidney Disease – Hiroshi Maekawa
4:57 p.m.	FR-OR34 Combination of Transcriptional Signatures and 3D Images of Epithelial
	Nuclei in Kidney Biopsies Using a Deep-Learning Outlier Detection Model Uncovers
	Signatures of Injury in Diabetic Kidney Disease – Seth Winfree
5:06 p.m.	FR-OR35 Identification of Early Diabetes-Induced Renal Changes Using Spatial
	Metabolomics – Rosalie Rietjens
5:15 p.m.	FR-OR36 Multi-Omics Integration Links Angiopoietin-Tie Signaling Pathway
	Activation With Diabetic Kidney Disease Progression – Viji Nair
5:24 p.m.	FR-OR37 A Prospective Study of Urinary Complement Proteins in Early Diabetic
	Kidney Disease in Type 1 Diabetes – Zaipul I Md Dom
5:33 p.m.	FR-OR38 Endogenous Retroviruses Contribute to Kidney Fibrosis Development by
·	Triggering the Innate Immune Response – Poonam Dhillon
5:42 p.m.	FR-OR39 A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to
·	Severe Diabetic Kidney Disease (MOSAIC) – Vlado Perkovic
5:51 p.m.	FR-OR40 Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal
·	Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-
	Controlled, Phase-1b/2a NEPHSTROM Clinical Trial – Matthew Griffin

	olyte, and Acid-Base Disorders Research	W308
Moderators: F	Robert Fenton, Evan Ray	
4:30 p.m.	FR-OR41 The Impact of Microgravity on Kidney Function During Spacefliq Keith Siew	jht –
4:39 p.m.	FR-OR42 Dietary Anion Controls Potassium Excretion: It's More Than a Po	orly
4.55 p.m.	Absorbable Anion Effect – Lama Al-Qusairi	City
4:48 p.m.	FR-OR43 Wearable Device for Continuous, Non-Invasive Monitoring of Se	rum
	Potassium in Hemodialysis Patients – Forrest Miller	
4:57 p.m.	FR-OR44 KCC3a, a Pathway for Potassium Loss in Alkalemia – Mohammed	Ferdaus
5:06 p.m.	FR-OR45 Complications and Treatment of Hypercalciuria in Familial Hype	rkalaemic
	Hypertension (FHHt) – Viola D'Ambrosio	
5:15 p.m.	FR-OR46 Insulin Receptor Substrate 4 (IRS4) Contributes to Hypomagnes	emia by
	Mediating the Insulin Effect on the Renal Magnesium Channel TRPM6 – N	/latthias Wolf
5:24 p.m.	FR-OR47 Salt-Sensitive Blood Pressure Response in CKD Is Not Volume M	ediated –
	Jetta Oppelaar	
5:33 p.m.	FR-OR48 In Vivo and In Vitro Effects of Hypoxia on NKCC2: Role of MAGE	-D2 –
	Kamel Laghmani	
5:42 p.m.	FR-OR49 One Size Does Not Fit All: Real World Data on the Safety of Bolu	IS
	Hypertonic Saline for Symptomatic Hyponatremia – Anissa Pelouto	
5:51 p.m.	FR-OR50 Thiazides Induce Glucose Intolerance Through Inhibition of Mit	ochondrial
	Carbonic Anhydrase 5b in β-Cells – Patrycja Kucharczyk	
Clamanular I	Diseases: From Bench to Bedside	10/414
	Samir Parikh, Bethany Roehm	
4:30 p.m.	FR-OR51 The Predictive and Prognostic Value of Antigen-Specific Memor	v R Call
4.30 p.m.	Levels in PLA2R-Associated Primary Membranous Nephropathy – Quanshi	•
4:39 p.m.	FR-OR52 APOL1 Promotes Endothelial Cell Activation Beyond the Glomer	
4.55 p.m.	Miguel Carracedo	uius –
1:19 n m	FR-OR53 Identification of Glomerular and Plasma APOM as Novel Biomar	kore in
4:48 p.m.	Glomerular Disease – Yelena Drexler	Keis III
4:57 p.m.	FR-OR54 Urinary CD4+ T Cell Quantification Identifies ANCA Patients at R	lick for
4.57 p.iii.	Subsequent Renal Flares: Results of the Prospective, Multicenter Pre-Flare	
	Luka Prskalo	a Study –
5:06 p.m.	FR-OR55 Explainability of a Deep Learning Based Classification Model for	ANCA-
3.00 p.m.	Associated Glomerulonephritis – Maria Wester Trejo	AITCA-
5:15 p.m.	FR-OR56 Sparsentan Improves Glomerular Endothelial and Podocyte Fund	tions and
3.13 p.111.	Augments Protective Tissue Repair in a Mouse Model of Focal Segmental	
	Glomerulosclerosis (FSGS) – Georgina Gyarmati	
5:24 p.m.	FR-OR57 Long-Term Efficacy and Safety of Sparsentan in FSGS: 240-Week	Analysis of
3.24 p.m.	the DUET Open-Label Extension (OLE) – Tarak Srivastava	Allulysis of
5:33 p.m.	FR-OR58 Efficacy and Safety of Voclosporin Over 3 Years in Patients With	Savara
3.33 p.iii.	Lupus Nephritis – Hanni Menn-Josephy	Jevere
5:42 p.m.	FR-OR59 Effect of Iptacopan on Proteinuria and Complement Biomarkers	Over Time
3.42 p.111.	in IgA Nephropathy – Brad Rovin	Over Time
5:51 p.m.	FR-OR60 A Multi-Omics Approach to IgA Nephropathy Characterization in	n the
J.J 1 P.111.	NUIDTUDE Cohort Enables Presision Posed Treatment Approaches N. Ols	

### Poster Sessions Friday, November 4 | West Exhibit Hall D

Poster Topics	Board #s
NIH/NIDDK and Informational Posters	INFO01–40
COVID-19: AKI Outcomes, Biomarkers, Treatments, Case Reports	001–059
AKI: Epidemiology, Risk Factors, Prevention	060–115
AKI: Mechanisms - II	116–175
Onconephrology: Clinical and Research Advances - I	176–215
Pharmacology	216–241
Genetic Diseases of the Kidneys: Cystic - II	
Genetic Diseases: Models, Mechanisms, Treatments	302–348
Genetics, Development, Regeneration	349–407
Pediatric Nephrology - I	408–450
Peritoneal Dialysis: Current Topics	
Home Dialysis, Policy, Novel Approaches	507–541
Fluid, Electrolyte, and Acid-Base Disorders: Clinical	542-574
Glomerular Diseases: Lupus and Vasculitis	575–633
Glomerular Diseases: Clinical, Outcomes, Trials - II	634–683
Glomerular Diseases: Podocyte Biology - I	684–734
Hypertension and CVD: Clinical, Outcomes, Trials	
Transplantation: Clinical - Biomarkers	762–805
Transplantation: Clinical - Outcomes	806–858
Diversity and Equity in Kidney Health - II	859–898
CKD: Epidemiology, Risk Factors, Prevention - II	899–949
CKD: Pathobiology - I	950–1009

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.



## EDUCATION AT YOUR FINGERTIPS







ASN has simplified your educational experience. Access thousands of expert presentations, test your knowledge with self-assessment programs, and earn CE credits/MOC points, all from the ASN eLearning Center.

For more information on this streamlined professional resource, visit asn-online.org/elearning or scan the QR code.

Questions? Email education@asn-online.org.



# The latest in nephrology science and news.



Learn more at www.asnjournals.org or scan the QR code using your phone camera.



## DAY-AT-A-GLANCE Saturday, November 5

8:00 a.m. – 9:30 a.m.	
Plenary: KidneyCure Announcement, Robert G. Narins Award, Belding H. Scribn	er Award,
Homer W. Smith Award and Address, State-of-the-Art Lecture	
9:30 a.m. – 2:30 p.m.	
Morning Break (9:30 a.m. – 10:00 a.m.)	West Exhibit Hall D
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)	
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)	
Tooler Trooperituations by Tuerrors (Toron units Tierror printy minimum minimu	TV CSC ZXGTC T CIT. Z
10:30 a.m. – 12:30 p.m.	
Basic/Clinical Science Sessions	
Nanodelivery in Organ Transplantation: Myth or Reality?	
Pediatric Dialysis: Innovations, (Quality) Improvements, and Insights	
Role of Basolateral Potassium Channel in Potassium Homeostasis and Diseases.	W230
Clinical Practice Sessions	
Advancing Home Dialysis with Technologies and Education	WF2 Tangerine
Kidney and Fluid: A Love-Hate Relationship	
Renal Biopsy: Clinical Correlations 2022	
Value-Based Payment Models Generating New Approaches to Kidney Disease C	
у	·-··-g-····-
Translational Sessions	
Calciprotein Particles and Calcification Propensity in CKD-MBD	W414
Imaging the Diabetic Kidney	
The Yellow Brick Road? Rethinking Clinical Development Strategies in AKI	W320 Chapin
Other Events	
Establishing Policy for Supportive Care in Kidney Health	W315
Innovate Kidney: KidneyX Innovators Showcase	
	********************************
12:45 p.m. – 1:45 p.m.	
Educational Symposia (Hyatt Regency Orlando) – Doors open at 12:30 p.m.	
Emerging Therapies for ANCA-Associated Vasculitis	Regency Ballroom R
Hyperkalemia: Understanding and Applying Innovative Approaches to	D D II C
the Management of CKD and ESKD	Regency Ballroom S
Recognizing and Managing the Itch of CKD-Associated Pruritus:	Danas a Dallas and T
Scratching the Surface	Regency Ballroom 1
2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
Genetics and Clinical Implications of APOL1 Nephropathy	WF1 Tangerine
Immunity: Friend and Foe in People on Dialysis	
Kidney and Genitourinary Development:	
Clinical Considerations for Pediatric Nephrologists	
Magnesium: The Forgotten Mineral	
Spatial Analysis of the Kidneys	W315
What's the Time in the Tubule?	W230

	_
2:00 p.m. – 4:00 p.m.	
Clinical Practice Sessions	
Antigens Underlying Glomerular Diseases: Diagnostic, Pathogenic, and Clinical Implication (Control of Control	
Nephrology Quiz and Questionnaire 2022	W304
Optimizing the Delivery, Safety, and Outcomes of Kidney Replacement Therapy in	14/207
People with AKIPerspectives on Personalized Nutrition Care in Kidney Diseases and	W307
Implementation Challenges	ME2 Tangarina
Reaching the Edge: Kidneys in Advanced Heart Failure	
Recurrent Glomerulonephritis After Kidney Transplantation:	VV311
Diagnostic and Therapeutic Approaches	WF3 Tangarina
Should Disease Names Change to Reflect Genotype, Pathology, or Phenotype, and	WI 5 Tallgeline
What Do Patients Think?	W320 Chanin
What Do Fatients Filmic.	W320 Chapin
Translational Sessions	
Kidney Biopsies and Diabetic Kidney Disease	W224
Thrifty Genes, Nephron Endowment, and Loss: AKI Lessons from Development,	
Pediatrics, and Aging, Including the Barry M. Brenner, MD, Endowed Lectureship	W308
4:00 p.m. – 4:30 p.m.	
Afternoon BreakWest Lobby D, West Lobby E/F, W415 Valencia Foyer,	and W320 Foyer
4:30 p.m. – 6:00 p.m.	
Basic/Clinical Science Sessions	N/F2 Tangarina
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session	
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session See the World Through a Different Lens:	W224
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session	W224
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health  Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session  See the World Through a Different Lens: Kidney Genomics Beyond Monogenic Disease	W224
Basic/Clinical Science Sessions  Leveraging Data Science to Improve Kidney Health  Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session  See the World Through a Different Lens:   Kidney Genomics Beyond Monogenic Disease  Clinical Practice Sessions	WF1 Tangerine
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 Tangerine
Basic/Clinical Science Sessions  Leveraging Data Science to Improve Kidney Health  Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session  See the World Through a Different Lens:   Kidney Genomics Beyond Monogenic Disease  Clinical Practice Sessions	WF1 Tangerine
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 Tangerine
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWS04WF3 Tangerine
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineW304WF3 Tangerine
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWS04WF3 TangerineWS30WS30
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWF3 TangerineWF3 TangerineWF3 WF3 WF3 WF3 WF3 WF3 WF3 WF3 WF3 WF3
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWF1 TangerineWF3 TangerineWF3 TangerineW230W308W414W307
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	W224WF1 TangerineW304WF3 TangerineW230W308W308
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWF1 TangerineWF3 TangerineWF3 TangerineW230W308W414W307
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWS04WF3 TangerineW230W308W307W240
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWS04WF3 TangerineW230W308W307W240
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWS04WF3 TangerineW230W308W307W240
Basic/Clinical Science Sessions Leveraging Data Science to Improve Kidney Health	WF1 TangerineWF1 TangerineWF3 TangerineWF3 TangerineW230W308W414W307W240

Download the meeting app or scan the QR code for more details and updates.



#### **Saturday, November 5, 8:00 a.m. – 9:30 a.m.**

Plenary: KidneyCure Announcement, Robert G. Narins Award,

Belding H. Scribner Award, Homer W. Smith Award and Address,	
State-of-the	-Art LectureW415 Valencia
8:00 a.m.	KidneyCure Announcement
8:10 a.m.	Robert G. Narins Award – Mark Perazella
8:20 a.m.	Belding H. Scribner Award – Phyllis August
8:30 a.m.	Homer W. Smith Award and Address "Urea Transport to Nephrogenic Diabetes
	Insipidus: Using Physiology to Develop Novel Therapy" – Jeff Sands
9:00 a.m.	State-of-the-Art Lecture "mRNA as Medicine" – Melissa Moore
	Saturday, November 5, 10:30 a.m. – 12:30 p.m.
	y in Organ Transplantation: Myth or Reality?WF3 Tangerine
	Daniel Heller, Martina McGrath
10:30 a.m.	Lymphoid Targeted Immune Therapy in Transplantation – Reza Abdi
11:00 a.m.	Stabilization of Cell-Cell Junctions: Novel Approach for Combating Ischemia
	Reperfusion Injury – Carl Atkinson
11:30 a.m.	Nanoparticle-Based Targeted Drug Delivery to Prevent Ischemia Reperfusion
	Injury in Kidney Transplantation – Satish Nadig
12:00 p.m.	Nanoparticle-Based Targeted Cellular Delivery in Transplantation –
	Xun-Rong Luo
Pediatric Dia	ulysis: Innovations, (Quality) Improvements, and InsightsW240
	Vimal Chadha, Vivian Shih
10:30 a.m.	New Innovations in Pediatric Dialysis – Ayse Akcan Arikan
11:00 a.m.	Dialysis as a CVD Risk Factor in Children: Mechanism and Management –
	Donald Weaver
11:30 a.m.	Improvements in Dialysis Care Related to Quality Improvement Initiatives –
	Rebecca Ruebner
12:00 p.m.	Children and Adolescents on Dialysis: Psychosocial Concerns and Caregiver
	Burden – Aaron Wightman, Taylor House
Role of Baso	lateral Potassium Channel in Potassium Homeostasis and DiseasesW230
Moderators:	Chou-Long Huang, Janet Klein
10:30 a.m.	Physiological and Pathophysiological Roles of Kir5.1 (KCNJ16) in the Kidneys – Alexander Staruschenko
11:00 a.m.	Kir4.1/Kir5.1 in the Distal Convoluted Tubule Regulates Potassium
	Homeostasis – WenHui Wang
11:30 a.m.	WNKs are Potassium-Sensitive Kinases – Aylin Rodan
12:00 p.m.	Next-Generation Inward Rectifier Potassium Channel Modulators:
	Discovery and Molecular Pharmacology – Jerod Denton

#### Saturday, November 5, 10:30 a.m. – 12:30 p.m.

<b>Advancing Ho</b>	ome Dialysis with Technologies and EducationWF2 Tangerine
Moderators: Li	sa Koester, Eric Weinhandl
10:30 a.m.	Kidney Disease Education – Jane Davis
11:00 a.m.	Can Transitional Dialysis Units Succeed? – Prayus Tailor
11:30 a.m.	Advancing Technologies in Home Dialysis – Brent Miller
12:00 p.m.	Transitioning of Modalities from Peritoneal Dialysis to Home Hemodialysis –
	Michael Kraus
<b>Kidney and Fl</b>	uid: A Love-Hate RelationshipW311
Moderators: G	abriel Contreras, Vandana Niyyar
10:30 a.m.	Fluid Management in Critically III Patients: To Fill or Not to Fill – Amir Kazory
11:00 a.m.	Assessment of Volume Status in Patients with ESKD: How Dry Is Dry? –
	Rajiv Agarwal
11:30 a.m.	Congestive Nephropathy in Heart Failure: Underrecognized and
	Underappreciated – Eddie Greene
12:00 p.m.	VExUS: Venous Excess Doppler Ultrasound for the Quantification and
	Monitoring of Venous Congestion – Abhilash Koratala
<b>Renal Biopsy:</b>	Clinical Correlations 2022W304
ASN thanks the	e Renal Pathology Society for assistance with this session.
Moderators: Je	ean Hou, Kelly Smith
Clinical Discuss	sant: Sean Barbour
10:30 a.m.	Renal Pathology Case Study 1 – Vivek Charu
11:00 a.m.	Renal Pathology Case Study 2 – Nicole Andeen
11:30 a.m.	Renal Pathology Case Study 3 – Renate Kain
12:00 p.m.	Renal Pathology Case Study 4 – Benjamin Adam
Value-Based F	Payment Models Generating New Approaches to
<b>Kidney Diseas</b>	se CareWF1 Tangerine
Moderators: Bi	rendan Bowman, Eugene Lin
10:30 a.m.	Push the Right Buttons for Better Kidney Disease Care: Value-Based Models –
	Daniel Weiner
11:00 a.m.	Going It Alone: The Kidney Care First Option – Gaurav Jain
11:30 a.m.	Together We Can Make It Happen: The Comprehensive Kidney Care
	Contracting Option – Dylan Steer
12:00 p.m.	Let Us Bring Our Team to You: Wrap-Around Kidney Care Companies –
	Shaminder Gupta
Calciprotein P	Particles and Calcification Propensity in CKD-MBDW414
	ecilia Giachelli, Anna Jovanovich
10:30 a.m.	Overview of Calciprotein Composition, Isolation, and Quantification
	Techniques – Edward Smith
11:00 a.m.	Mechanisms of Calciprotein Formation and Processing – Willi Jahnen-Dechent
11:30 a.m.	Calciprotein Particles as Drivers of Inflammation and Cellular Damage –
	Elisabeth Jaeger
12:00 p.m.	Utility of Calcification Propensity Assays for Predicting Vascular Calcification –
	Wei Chen

#### Saturday, November 5, 10:30 a.m. – 12:30 p.m.

Imaging the I	Diabetic KidneyW224
Moderators: K	umar Sharma, Anand Srivastava
10:30 a.m.	Imaging Oxygenation – Petter Bjornstad
11:00 a.m.	Imaging Fat Content in the Kidney Parenchyma and More with Multiparametric Kidney MRI – TBD
11:30 a.m.	Infrared Spectroscopic Imaging – Michael Walsh
12:00 p.m.	The BEAt-DKD Imaging Experience – Steven Sourbron
	rick Road? Rethinking Clinical Development Strategies in AKIW320 Chapin
	avier Neyra, Danielle Soranno
10:30 a.m.	What Makes for an Exciting Preclinical Data Packet for AKI or CKD? – Katalin Susztak
11:00 a.m.	Rethinking End Points in Early Phase AKI Studies – Sushrut Waikar
11:30 a.m.	An Adaptive Trial Platform for AKI? Promises and Perils – Kathleen Liu
12:00 p.m.	Lessons for AKI Research from Pragmatic Trials – Miguel Vazquez
Establishing F	Policy for Supportive Care in Kidney HealthW315
Note: Continui	ing education credits are not being offered for this activity.
Innovate Kidr	ney: KidneyX Innovators ShowcaseWest Exhibit Hall D
Note: Continui	ng education credits are not being offered for this activity.
	Saturday, November 5, 12:45 p.m. – 1:45 p.m.
Ec	<b>fucational Symposia (Hyatt Regency Orlando)</b> – Doors open at 12:30 p.m.
Lunch is pro	vided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.
	erapies for ANCA-Associated VasculitisRegency Ballroom R
	rided by an educational grant from ChemoCentryx, Inc.
12:45 p.m.	Introduction – Ulf Panzer (Moderator)
12:55 p.m.	Pathogenesis and Diagnostic Approaches to ANCA Vasculitis – Ingeborg Bajema
1:15 p.m.	Updates on the Treatment of ANCA Vasculitis – Rachel Jones
1:35 p.m.	Questions and Answers
	a: Understanding and Applying Innovative Approaches to
_	nent of CKD and ESKDRegency Ballroom S
	vided by an educational grant from AstraZeneca Pharmaceuticals.
12:45 p.m.	Introduction: The Physiology of Hyperkalemia – Kim Zuber (Moderator)
12:55 p.m.	The Impact of Hyperkalemia in the Treatment of CKD – Mitchell Rosner
1:15 p.m.	Pharmacological and Nonpharmacological Approaches to the Management of Hyperkalemia – Biff Palmer
1:35 p.m.	Questions and Answers
	and Managing the Itch of CKD-Associated Pruritus:
	e SurfaceRegency Ballroom T
	vided by an educational grant from CSL Vifor.
12:45 p.m.	Introduction – Denise Link (Moderator)
12:55 p.m.	Pathogenesis and Diagnosis of CKD-Associated Pruritus – Sara Combs
1:15 p.m.	Optimal Treatment and Management Strategies for CKD-Associated Pruritus – David Steele
1:35 p.m.	Questions and Answers

Genetics and	d Clinical Implications of APOL1 Nephropathy	WF1 Tangerine
Moderators:	Opeyemi Olabisi, John Sedor	
2:00 p.m.	Population Genetics of APOL1 and Its Clinical Spectrum	
2:30 p.m.	APOL1 and Potential Implications for Kidney Transplar	ntation – Barry Freedman
3:00 p.m.	Biology of APOL1 Nephropathy – Martin Pollak	
3:30 p.m.	Therapeutic Development in APOL1 Nephropathy – Og	jo Egbuna
Immunity: F	riend and Foe in People on Dialysis	
	Simon Davies, Jennifer Flythe	
2:00 p.m.	Adverse Consequences of Immune Dysregulation in Di	alysis Patients – Talat Alp Ikizle
2:30 p.m.	Responses to Vaccines and Viruses in Dialysis Patients	
3:00 p.m.	Infection Prevention and Control: Lessons from Childre	•
3:30 p.m.	Innate Immunity in Dialysis Patients – Anne-Catherine R	•
Kidney and	Genitourinary Development: Clinical Considerations for	
	ephrologists	W240
	Susan Furth, Michelle Starr	
2:00 p.m.	Making Sense of a Moving Target: Kidney Function and	d Dysfunction During
2.00 p	Periods of Rapid Growth – Marissa Defreitas	
2:30 p.m.	Little Kidneys, Big Problems: Prematurity and Small Kid	dnev Size as Risk Factors
2.50 p	for CKD – Jennifer Charlton	
3:00 p.m.	Running on Empty: Barriers to Urinary Drainage and A	ssociated Clinical
	Implications – Brian Becknell	
3:30 p.m.	Medical Conditions and Interventions That Impact Kidi	nev Development:
	Pregnancy and Beyond – Keia Sanderson	,
Magnesium	: The Forgotten Mineral	W414
	Diana Jalal, Cesar Romero	
2:00 p.m.	Role of the Kidneys in Magnesium Homeostasis - Joost	: Hoenderop
2:30 p.m.	Genetic and Clinical Factors Associated with Magnesius	•
•	Population – John Lieske	
3:00 p.m.	Magnesium and the Molecular Mechanisms Driving Va	scular Calcification –
•	Jeroen De Baaij	
3:30 p.m.	Clinical Evidence for a Role of Magnesium Deficiency in	<b>n CVD</b> – Mirela Dobre
Spatial Anal	lysis of the Kidneys	W315
	Daria Barwinska, Zoltan Laszik	
2:00 p.m.	Spatial Transcriptomics of the Kidneys – Laura Perin	
2:30 p.m.	Spatial Metabolomics in Human Kidneys – Kumar Sharn	na
3:00 p.m.	Spatial Analysis of Immune Cells in the Kidneys – Marci	
3:30 p.m.	Imaging Mass Cytometry of the Human Kidneys - Lloyd	

	me in the Tubule?W230
	lirupama Ramkumar, Tianxin Yang
2:00 p.m.	Circadian Regulation of Kidney Sodium Handling: Systemic Clock – David Pollock
2:30 p.m.	Circadian Regulation of Kidney Sodium Handling: Tubular Clock – Lauren Douma
3:00 p.m.	Tubular Clock Regulates Kidney Glucose Handling – Xiaoyue Pan
3:30 p.m.	Environmental Circadian Disruption and Kidney Function Rhythm and Injury – Alec Davidson
Antigens Und	lerlying Glomerular Diseases: Diagnostic, Pathogenic, and
	cationsW314
	vided by an educational grant from Travere Therapeutics, Inc.
	iffany Caza, Shikha Wadhwani
2:00 p.m.	New Antigens in Membranous Nephropathy: Unique Clinicopathologic Features – Sanjeev Sethi
2:30 p.m.	New Antigens in Membranous Nephropathy: Potential Importance in Prognosis and Treatment – Elion Hoxha
3:00 p.m.	Recent Insights into the Pathogenesis of ANCA Glomerulonephritis and  Vasculitis – Duvuru Geetha
3:30 p.m.	Infectious Antigens and Glomerulonephritis: An Update – Samih Nasr
Nephrology (	Quiz and Questionnaire 2022W304
Moderators: N	Melanie Hoenig, Michael Ross
2:00 p.m.	Electrolyte and Acid-Base Disturbances – Roger Rodby
2:30 p.m.	Glomerular Diseases – Pietro Canetta
3:00 p.m.	Transplantation – Beatrice Concepcion
3:30 p.m.	Renal Replacement Therapy – Nisha Bansal
	ne Delivery, Safety, and Outcomes of Kidney Replacement Therapy in
	AKIW307
	asheed Balogun, Luis Juncos
2:00 p.m.	Evidence and Gaps Underpinning Current RRT Practice in the Intensive Care Unit – Ashita Tolwani
2:30 p.m.	"First, Do No Harm": latrogenic Complications of Acute Kidney Replacement Therapy – Anitha Vijayan
3:00 p.m.	Using Data to Drive Improvement in the Clinical Outcomes of Kidney
5.00 p.m.	Replacement Therapy in AKI – Javier Neyra
3:30 p.m.	Leading the Charge: Organizational Considerations in AKI Survivor Care –
3.30 p.111.	Stuart Goldstein

Perspectives	s on Personalized Nutrition Care in Kidney Diseases and
Implementa	tion ChallengesWF2 Tangerine
Moderators:	Casey Rebholz, Jaime Uribarri
2:00 p.m.	Plant-Based Diets to Control CKD Progression in Adults and Children –
	Connie Rhee
2:30 p.m.	Personalized Nutrition Care: What Is It and How Can It Be Implemented? –
·	Carla Avesani
3:00 p.m.	Assessing Global Kidney Nutrition Care: A Collaborative Initiative from the
·	International Society of Renal Nutrition and Metabolism and International
	Society of Nephrology Global Kidney Health Atlas – Angela Yee Moon Wang
3:30 p.m.	Living with a Kidney Diet: A Patient's Perspective – Dawn Edwards
· ·	•
Reaching th	e Edge: Kidneys in Advanced Heart FailureW311
	Kianoush Kashani, Amir Kazory
2:00 p.m.	The Art of Volume Management in Heart Failure: From Assessment to
	Therapy – W.H. Wilson Tang
2:30 p.m.	Focus on POCUS: Can Point-of-Care Ultrasound Change Our Approach in
2.50 p.m.	Cardiorenal Syndrome? – Abhilash Koratala
3:00 p.m.	Love-Hate Relationship Between Kidney and Mechanical Circulatory Support
5.00 p	<b>Devices</b> – Jeffrey Turner
3:30 p.m.	Inferior Vena Cava Ultrasound: Pearls and Pitfalls – Elaine Kaptein
3.30 p.m.	interior vena dava ora abbana. Pearis ana Pradis
Recurrent G	lomerulonephritis After Kidney Transplantation: Diagnostic and
	ApproachesWF3 Tangerine
	ovided by an educational grant from Travere Therapeutics, Inc.
	Nicolae Leca, Deirdre Sawinski
2:00 p.m.	Recurrence of FSGS After Kidney Transplantation – Leonardo Riella
2:30 p.m.	Recurrent Primary FSGS: Insights into the Pathogenesis of FSGS –
2.30 p.m.	Lorenzo Gallon
3:00 p.m.	APOL1 in Kidney Transplantation – Mona Doshi
3:30 p.m.	Recurrent Membranous Nephropathy: Diagnostic and Therapeutic Approach –
3.30 p.m.	Fernando Fervenza
	i emando i ervenza
Should Disa	ase Names Change to Reflect Genotype, Pathology, or Phenotype,
	o Patients Think?W320 Chapin
	ovided by an educational grant from Travere Therapeutics, Inc.
	Rasheed Gbadegesin, Catherine Quinlan
2:00 p.m.	Defining the Molecular Basis of Glomerular Disease – Matthias Kretzler
2:30 p.m.	Change the Name: Genetics-Focused Naming – Alicia Byrne
	Retain the Name: Pathology-Focused Naming – Astrid Weins
3:00 p.m. 3:30 p.m.	Patient Perspective: Implications of Naming for Alport Syndrome – Susie Gear
5.50 p.m.	Patient Perspective: Implications of Naming for Alport Syndrome – Susie Geal
Kidney Rich	sies and Diabetic Kidney DiseaseW224
	Eoin Brennan, Parker Wilson
2:00 p.m.	Historical Learnings on Kidney Pathology in Diabetes – Paola Fioretto
2:30 p.m.	Biopsy Findings in the Pima Population – Behzad Najafian
3:00 p.m.	Kidney Biopsies and Molecular Assessment of Kidney Disease – Andrew Malone
3:30 p.m.	Digital Pathology for Diabetic Kidney Disease – Vijaya Kolachalama
5.50 p.111.	Digital Facilities 101 Diabetic Riulies Disease - Vijaya Rolaciididild

#### 

Endowed Lectureship.

Moderators: Amanda Clark, Prasad Devarajan

2:00 p.m. Developmentally Programming a Healthy Kidney: The Barry M. Brenner, MD,

**Endowed Lectureship** – Andrew McMahon

2:30 p.m. Applying Organoids to Interrogate AKI Mechanisms – Kyle McCracken

3:00 p.m. How Children and Adults Differ in Terms of AKI Susceptibility and Outcomes -

Shina Menon

3:30 p.m. Influence of Aging Mechanisms on AKI Risk – Karl Nath

#### Saturday, November 5, 4:30 p.m. – 6:00 p.m.

#### Leveraging Data Science to Improve Kidney Health ......WF2 Tangerine

ASN thanks the ASN AKINow Workgroup for assistance with this session.

Moderators: Sherry Mansour, Motoko Yanagita

4:30 p.m. What Is the Full Potential of Electronic Medical Record Data in

Relation to AKI? - Girish Nadkarni

4:50 p.m. Let's Talk Sequencing: What We Know and What the Future Holds –

Parker Wilson

5:10 p.m. Multi-Omics and Multi-Advancements in Kidney Health – Morgan Grams
5:30 p.m. Learning About Machine Learning: How Effective Is It in Relation to AKI? –

Ashish Verma

#### Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session ......W224

ASN thanks the American Diabetes Association for assistance with this session.

Moderators: Josephine Forbes, Padmanabhan Subramanian

4:30 p.m. **Dietary Factors** – Matthew Snelson

4:50 p.m. **Autophagy** – Reiko Inagi

5:10 p.m.
Sphingolipids – Sandra Merscher
5:30 p.m.
Mitochondria – Krisztian Stadler

#### See the World Through a Different Lens: Kidney Genomics Beyond

#### Monogenic Disease ......WF1 Tangerine

Moderators: Rafael Kramann, Matt Sampson

4:30 p.m. AKI Genotype, Susceptibility, and the Potential for Personalized Medicine –

**Emily See** 

4:55 p.m. X-Linked Kidney Diseases in XX Patients – Michelle Rheault

5:20 p.m. Barriers and Facilitators to the Implementation of Discovery Genomics in

Routine Health Care - Daniel Gale

#### Best of NephJC ......W304

ASN thanks NephJC for assistance with this session.

Moderators: Swapnil Hiremath, Caitlyn Vlasschaert

4:30 p.m.
4:50 p.m.
Best of Hypertension Literature – Jade Teakell
4:50 p.m.
Best of Dialysis Literature – Graham Abra

5:10 p.m. Best of AKI Literature – Francis Wilson

5:30 p.m. Best of Basic Science Literature for the Clinician – Kelly Hyndman

The Many Fa	ces of Drug-Induced Kidney InjuryWF3 Tangerine
Moderators: N	Melanie Joy, Namrata Krishnan
4:30 p.m.	Acute Tubular Injury Associated with Medications: A Focus on Mitochondrial
	Toxicity – Mohamed Atta
4:50 p.m.	Crystalline-Induced AKI from Medications: It's More Than Tubular
	Obstruction – Felix Knauf
5:10 p.m.	Vancomycin-Associated AKI, Three of a Kind: Acute Tubular Injury, Acute
	Interstitial Nephritis, and Cast Nephropathy – Erin Barreto
5:30 p.m.	Drug-Induced Acute Interstitial Nephritis: The Great Masquerader –
	Maria Prendecki
Innovate Kid	ney Challanges on Clinical Trials for Novel Kidney Drugs and

#### Innovate Kidney: Challenges on Clinical Trials for Novel Kidney Drugs and Meet-and-Greet the Kidney Health Initiative Board.......W315

Note: Continuing education credits are not being offered for this activity.

#### Oral Abstract Sessions

Of all Abstract Sessions		
Kidney Diseases: Mechanisms and ManagementW230		
eghan Sise, Jacob Stevens		
SA-OR01 Long-Term Renal Outcomes of COVID-19-Associated Nephropathy		
(COVAN) – Gabriel Giannini		
SA-OR02 Renal Pathology of Fatal Cases of COVID-19: A Study of 94 Autopsies –		
Arian Pourmehdi Lahiji		
SA-OR03 Incidence and Clinical Course of Gross Hematuria Following COVID-19		
Vaccination Among Patients With IgA Nephropathy – Hitomi Kimura		
SA-OR04 Urinary Transcriptomics Identified Inflammatory Signals Associated With		
COVID-19-Related AKI – Sean Eddy		
SA-OR05 Single Nucleus RNA-Sequencing in Diagnostic Biopsy Cores of COVID-AKI		
Patients Reveals Robust Modelling, Injury, and Profibrotic Markers – Reetika Ghag		
SA-OR06 Kidney Disease and COVID-19 Outcomes in the Temporal Analysis of		
Pandemic Waves – Ning Shang		
SA-OR07 COVID-19 Pandemic Effect on Mortality of Hemodialysis Patients –		
Yan Zhang		
SA-OR08 Vaccine Effectiveness of One, Two, or Three Doses of SARS-CoV-2 mRNA		
Vaccines in Maintenance Dialysis Patients – Harold Manley		
SA-OR09 Clinical Efficacy of the Fourth Dose of the BNT162b2 Vaccine in Chronic		
Dialysis Patients – Moshe Shashar		
SA-OR10 BOOST KIDNEY: A Randomized Controlled Trial of Third Dose BNT162b2 vs.		
mRNA-1273 COVID-19 Vaccination in CKD and Dialysis Patients – Kevin Yau		

Genetics, Deve	lopment, and TherapiesW308
Moderators: Sa	tu Kuure, Kameswaran Surendran
4:30 p.m.	SA-OR11 Genome-Wide Association Studies of a Composite Renal Phenotype Reveal
	Pleiotropic Effects and a Novel Locus – Moumita Barua
4:39 p.m.	SA-OR12 Gene Surgery: A Potential CRISPR/Cas-Based Treatment Option for
	Nephropathic Cystinosis In Vitro – Elena Sendino Garví
4:48 p.m.	SA-OR13 Channel Function of Polycystin-2 in Endoplasmic Reticulum Protects
	Against Polycystic Kidney Disease – Biswajit Padhy
4:57 p.m.	SA-OR14 Downregulation of O-GlcNAc Reduces Ciliary Length and Attenuates Renal
	Cystic Disease in PKD Mice – Matthew Kavanaugh
5:06 p.m.	SA-OR15 The Methionine-Mettl3-RNA Methylation Axis Is Essential for
	Nephrogenesis – Harini Ramalingam
5:15 p.m.	SA-OR16 Estrogen Signaling Is an Essential Regulator of Nephron Segmentation –
	Hannah Wesselman
5:24 p.m.	SA-OR17 Interstitial Notch Signaling Is Required for the Development of Proximal
	Tubules – Joo-Seop Park
5:33 p.m.	SA-OR18 ASH2L Is Essential for the Ureteric Bud Lineage Development – Ziyi Zhao
5:42 p.m.	SA-OR19 Establishing the Spatiotemporal Organization and Function of Renal Nerves
	Throughout Nephrogenesis – Pierre-Emmanuel N'Guetta
5:51 p.m.	SA-OR20 Deciphering the Origins of Kidney Lymphatics – Daniyal Jafree
Clamanular Dir	Machaniana of Callular Inium
	seases: Mechanisms of Cellular Injury
4:30 p.m.	SA-OR21 Tenascin-C Promotes Migration and Proliferation of Parietal Epithelial Cells
4.50 p.m.	and Participates in the Pathogenesis of FSGS – Ke Sun
4.20 n m	SA-OR22 Cell-Specific Role of STAT3 Signaling in Podocytes vs. Parietal Epithelial
4:39 p.m.	Cells in Proliferative Glomerulopathy – Yogesh Gowthaman
4:48 p.m.	SA-OR23 Continuous Non-Mutagenic DNA Damage in Podocytes Activates
4.40 p.m.	Pathogenic Memory T Cells Through Altered DNA Methylation – Ran Nakamichi
4:57 p.m.	SA-OR24 y Isoform of Phosphoinositide 3 Kinase Plays a Critical Role in Propagation
4.57 p.m.	of Podocyte Injury in a Genetic Podocytopathy – Xiaoyan Liang
5:06 p.m.	SA-OR25 A Possible Role of Anti-Nephrin Autoantibody in Endocytosis of Nephrin in
3.00 p.m.	Patients With Post-Transplant Focal Segmental Glomerulosclerosis Recurrence and
	Minimal Change Disease – Yoko Shirai
5:15 p.m.	SA-OR26 Podocyte-Specific Loss of Klf4 Induces the Formation of Extracellular
3.13 p.iii.	Matrix Extensions – Nina Cintron Pregosin
5:24 p.m.	SA-OR27 RCAN1 I162T Variant Disrupts Calcineurin Regulation and Reduces Viability
3.24 p.111.	in Patient-Derived Podocytes – Kinsie Huggins
5:33 p.m.	SA-OR28 C3a/C3aR1 Signaling as a Crucial Pathogenic Mechanism in Membranous
3.33 p.iii.	Nephropathy – Stefano Da Sacco
5:42 p.m.	SA-OR29 Targeting the Integrated Stress Response Pathway in T Cells Ameliorates
p	Crescentic Glomerulonephritis in Mice – Nariaki Asada

High-Impact	CKD Potpourri: Something for EveryoneW307
Moderators: N	Nayan Arora, Tanjala Purnell
4:30 p.m.	SA-OR31 Linked by Love: Relatability and Cultural Appropriateness of an
	Edutainment Series About CKD in an African American Family – LaShara Davis
4:39 p.m.	SA-OR32 A Randomized Controlled Pilot Study of a Patient Decision Aid About
·	Conservative Kidney Management – Susan Wong
4:48 p.m.	SA-OR33 Impact of Race/Ethnicity and Age on Hospitalization Outcomes in Advanced CKD Patients Treated With Conservative Management vs. Dialysis –
4.57	Connie Rhee
4:57 p.m.	SA-OR34 Prevalence of CKD Among Asian Adults in the United States, 2011-2018 –
<b>5.00</b>	Sophie Claudel
5:06 p.m.	SA-OR35 Comparison of Clinical Outcomes Between Twice- vs. Thrice-Weekly
	Hemodialysis in Thai Elderly Patients: A Single-Center Study – Prapa Pattrapornpisut
5:15 p.m.	SA-OR36 Effects of Dapagliflozin on Anemia in Patients With CKD With or Without
	Type 2 Diabetes: A Pre-Specified Analysis of the DAPA-CKD Trial – Hiddo Heerspink
5:24 p.m.	SA-OR37 Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of Major
	Adverse Cardiovascular Events in the ASCEND Trials – Gregorio Obrador
5:33 p.m.	SA-OR38 Change in Albuminuria and GFR Slope as Joint Surrogate End Points for
	Kidney Failure: Implications for Phase 2 Trials – Tom Greene
5:42 p.m.	SA-OR39 Effect of a Nutritional Supplement of Probiotics and/or Prebiotics vs.
	Placebo on Nutritional Status in Automated Peritoneal Dialysis (APD) Patients –
	Fabiola Martin del Campo
5:51 p.m.	SA-OR40 Obesity Weight Loss Phenotypes in CKD: Data From the Chronic Renal
	Insufficiency Cohort Study (CRIC) – Meera Harhay
	ion: Clinical Outcomes and BiomarkersW240
	uz Liriano-Ward, Alexander Wiseman
4:30 p.m.	SA-OR41 Utilization of SARS-CoV-2 (COVID-19)-Positive Donor Kidneys –
	Warren Mckinney
4:39 p.m.	SA-OR42 Viro-Immunological Monitoring as a Predictor for Complicative Events in
	the First Year After Kidney Transplantation: The VIRENO Study – Patrick Affeldt
4:48 p.m.	SA-OR43 A Randomized Phase 2 Study of MAU868 vs. Placebo to Treat BK Viremia in
	Kidney Transplant Recipients – Stanley Jordan
4:57 p.m.	SA-OR44 Spatial mRNA Analysis of Human Allograft Endothelium Shows Distinct
	Structure-Specific Endothelial Transcripts in Chronic Antibody-Mediated Rejection –
	Ira Doressa Anne How
5:06 p.m.	SA-OR45 Acute Tubular Injury and Necrosis Do Not Lead to Meaningful Elevations in
	Donor-Derived Cell-Free DNA (dd-cfDNA) – Sridhar Reddy Allam
5:15 p.m.	SA-OR46 Validation of a Urinary Exosome mRNA Signature for the Diagnosis of
·	Human Kidney Transplant Rejection – Rania El Fekih
5:24 p.m.	SA-OR47 Five-Year Follow-Up of a Phase 1 Trial of Donor-Derived Modified Immune
	Cell Infusion in Kidney Transplantation – Matthias Schaier
5:33 p.m.	SA-OR48 A Regimen of Nonmyeloablative Conditioning and CD8+/TCR- Facilitating
5.55 p	Cells Tips the Balance Towards Immune Downregulation and Away From Cytopathic
	Activity in Kidney Allograft Recipients – John Lee
5:42 p.m.	SA-OR49 Clinical Performance Validation of Tuteva Biomarker – Oriol Bestard
5:51 p.m.	SA-OR50 Immune Cell Transcriptome in Living-Donor Kidney Transplant Patients
3.31 p.iii.	Tolerized With Allogeneic Hematopoietic Stem Cell Transplantation Therapy –
	• • • • • • • • • • • • • • • • • • • •
	Jennifer McDaniels

## Poster Sessions Saturday, November 5 | West Exhibit Hall D

Poster Topics	Board #s
NIH/NIDDK and Informational Posters	
Bioengineering	
AKI: Important, Yet Underappreciated Causes	
AKI: Mechanisms - III	
Onconephrology: Clinical and Research Advances - II	
Vascular Calcification, Nephrolithiasis, Bone	
Diabetic Kidney Disease: Basic - II	
Diabetic Kidney Disease: Clinical - II	257–284
Hemodialysis and Frequent Dialysis: Potpourri	285–344
Hemodialysis and Frequent Dialysis: CV and Risk Prediction	
Hemodialysis and Frequent Dialysis: Clearance, Technology, Infection	405–464
Fluid, Electrolyte, and Acid-Base Disorders: Case Reports	465–521
Genetic Diseases: Diagnosis	522–583
Pediatric Nephrology - II	
Glomerular Diseases: IgA and Complement-Mediated GN	
Glomerular Diseases: Clinical, Outcomes, Trials - III	678–730
Glomerular Diseases: Podocyte Biology - II	731–752
Hypertension and CVD: Mechanisms	753–793
Transplantation: Clinical - Pretransplant Assessment and Living Donors	794–839
Transplantation: Clinical - Case Reports	840–884
CKD: Clinical Trials and Pharmacoepidemiology	885–919
CKD: Observational Research and Patient-Oriented Interventions	
CKD: Pathobiology - II	955–1013

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.

#### **Kidney Week Virtual Platform**

All meeting content will be available on the virtual meeting platform for in-person and virtual participants through Wednesday, December 21, 2022.

Log in at www.asn-online.org/kwplatform.



## Scientific Exposition

A vital part of the Kidney Week educational experience is found on the scientific exposition floor. West Exhibit Hall D, of the Orange County Convention Center. This unparalleled international venue provides demonstrations of products and services that will enhance vour understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care. On the exposition hall floor, you can engage in peer-to-peer interactions with representatives and businesses that form an integral part of your day-to-day fight against kidney disease and view thousands of accepted poster abstracts.

ASN is a member of the Healthcare Convention and Exhibitors Association (HCEA).



#### **Exhibit Hall & Posters Hours**

Thursday Nov. 3

9:30 a.m. - 2:30 p.m.

Friday

Nov. 4

9:30 a.m. - 2:30 p.m.

Saturday

Nov. 5

9:30 a.m. - 2:30 p.m.

The Welcome Reception is supported by Fresenius Medical Care Renal Pharmaceuticals.

Scientific Exposition Refreshment Breaks are supported by ANI Pharmaceuticals, Inc.

Attendee Lounges are supported by GSK.

#### Exhibitor Spotlight Schedule

Join your colleagues for the latest advances in nephrology practices. products, services, and technologies presented in two theaters on the exhibit hall floor (no continuing education credit). Seating is limited and available on a first-come, first-served basis.

All presentations include breakfast or lunch.

#### **Thursday, November 3**

10-10:45 a.m.

Jardiance® (empagliflozin) tablets: EMPEROR Clinical Trials Data Subgroup Analyses





12:30-1:15 p.m.

Are You Thinking Genetic? The Emerging Role of Genetics in CKD

Presented by \* natera

#### Friday, November 4

10-10:45 a.m.

Understanding the Complexity of Patients with CKD: Implications for Management



12:30-1:15 p.m.

Developing Precision Medicines for Patients with IgAN

Presented by



#### Saturday, November 5

10-10:45 a.m.

Physician-Patient Discussion: Does Patient Care Need to Evolve for Anemia of CKD?

Presented by



**Medical Affairs** 

12:30-1:15 p.m.

The Phosphorus Management Puzzle and Need for New Pieces: The Patient and Physician Perspective



#### **Thursday, November 3**

11:30 a.m.-12:15 p.m.

The Cardiorenal Connection: Providing Dual Cardiorenal Risk Reduction for Patients with CKD Associated with T2D

Presented by



#### 1-1:45 p.m. Perspectives on OmniGraf Use in Clinical Practice



Diagnostics

#### Friday, November 4

11:30 a.m.-12:15 p.m.

New Data on an Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment Option

Presented by



Otsuka America Pharmaceutical, Inc.

#### 1-1:45 p.m.

The Importance of Achieving a Complete Response in Lupus Nephritis



#### Saturday, November 5

11:30 a.m.-12:15 p.m. Surveillance Tools and Molecular **Innovation for Transplant Patients** 



#### 1-1:45 p.m.

First Steps for Females with GLA Variants Detected by Kidney Disease Panels: Actionable Findings

Presented by Sanofi

These events are not CE (continuing education) activities.





## Patient Care

Excellence in Patient Care (EPC) focuses on ASN's clinical priorities to provide high-quality care for people with kidney diseases. Key contributors include patient advocates, members of the kidney care team, and partners across the kidney community.

#### **KIDNEY WEEK EVENTS**

COVID-19	DKD	AKINow
Thursday, 11/3 2:00 – 4:00 p.m. A Look in the Crystal Ball: COVID-19 and the Future of Outpatient Dialysis	Thursday, 11/3 10:30 a.m. – 12:30 p.m. The Patient Journey with Diabetic Kidney Disease	Saturday, 11/5 4:30 - 6:00 p.m. Leveraging Data Science to Improve Kidney Health

#### **EPC PROJECTS AND INITIATIVES**

- Nephrologists Transforming Dialysis Safety (NTDS) promotes transformational change that continuously improves the safety of dialysis
- Quality Assessment, Improvement, & Education (QAIE) creates and distributes infection prevention resources and best practices
- Current and Emerging Threats (CET) provides education and resources in the area of current and emerging bacterial, viral, and fungal threats
- Human Factors Engineering identifies facilitators and barriers to increased patient and staff safety through the study of human factors – "work as imagined versus work as performed"
- Transforming Dialysis Access Together (TDAT) pursues dialysis access justice, equity, diversity, and inclusion in medical training and patient care
- Diabetic Kidney Disease Collaborative (DKD-C) works together to address the urgent and unmet needs in the diagnosis and treatment of people with DKD
- COVID-19 response develops and disseminates resources to the kidney community during the current pandemic, and preparing for future crises
- AKINow promotes excellence in the prevention and treatment of acute kidney injury (AKI)
- Adult Immunization Project (AIP) advocates for the adoption of CDC's Standards of Adult Immunization Practices in kidney care
- Home Dialysis Project (HDP) fosters awareness of and improved outcomes for home dialysis therapies and addressing disparities in access to home dialysis











The ASN Research Discovery and Innovation department integrates three programs to stimulate, accelerate, and support biomedical research and innovations for people with kidney diseases.

- **KidneyCure** encourages and supports the kidney research and education workforce through grants and fellowships to pre-doctoral through early-career researchers.
- Kidney Health Initiative promotes the development of innovative treatment options for people with kidney diseases through a partnership between ASN, the US Food and Drug Administration, and over 100 member organizations.
- **KidneyX** is a partnership between ASN and the US Department of Health and Human Services that enables the development of breakthrough treatments in kidney care.

#### **DAY-AT-A-GLANCE Sunday, November 6**

#### **DAY-AT-A-GLANCE: Sunday, November 6**

Plenary: Midcareer Awards, State-of-the-Art Lecture	W415 Valencia
ASN Business Meeting	W415 Valenci
9:30 a.m. – 11:30 a.m.	
Basic/Clinical Science Sessions	
AKI: Old and New Players	W31
AKI: Old and New Players Nephron Progenitor Fate Determination and Maintenance	W31
Clinical Practice Sessions	
Contemporary Management of Diabetic Kidney Disease:	
Update on Recent Clinical Trials	W415 Valenci
Ethical Challenges in Nephrology, Including the Christopher R. Blagg, MD,	
Endowed Lectureship in Kidney Diseases and Public Policy	W304
Glomerular Diseases and Cancer: Cause or Effect?	W41
Pending Challenges When Addressing Donor Kidney Function:	
How Low Is Low Before and After Donation	W30
Translational Session	
Molecular Mechanisms of Hypertension and Cardiovascular Effects	14/20

### Kidney Week On-Demand

Never miss a session with
Kidney Week On-Demand 2022.
With 200+ hours of recorded
Annual Meeting presentations,
Kidney Week On-Demand is the
best way to get the most out of your
Annual Meeting registration. To get your
complimentary access code, exchange
the voucher in your meeting bag at Vertex
Pharmaceuticals Booth 1901. Access codes
are available during Exhibit Hall hours to
fully Paid Annual Meeting participants only. All
recorded Presentations will be available in the
ASN eLearning Center in January 2022.

#### Kidney Week On-Demand Voucher

Never miss a session with Kidney Week On-Demand 2022. With over 200 hours of recorded Annual Meeting presentations, Kidney Week On-Demand is the best way to get the most out of your Annual Meeting experience. To get your complimentary access code, exchange this voucher at the following booth:



#### Booth 1901

All recorded presentations will be available in January 2023 on the ASN eLearning Center for up to three years.

Access codes are available during Exhibit Hall hours to fully paid Annual Meeting participants only.

KIDNEY WEEK B

Note: Continuing education credits are not available for Kidney Week On-Demand.

#### Sunday, November 6, 8:00 a.m. - 9:00 a.m. 8:00 a.m. In Memoriam 8:05 a.m. Midcareer Awards 8:15 a.m. State-of-the-Art Lecture "Wearable Microfluidic Devices and Implantable Electronic Systems for Kidney Health" – John Rogers ASN Business Meeting......W415 Valencia Sunday, November 6, 9:30 a.m. – 11:30 a.m. AKI: Old and New Players......W311 Moderators: Pierre Dagher, Kimberly Reidy 9:30 a.m. Protective Neural Circuits in AKI - Mark Okusa 10:00 a.m. Dysregulation of Iron Metabolism in AKI – Subhashini Bolisetty 10:30 a.m. Manipulating Fatty Acid Oxidation to Protect Against AKI – Sunder Sims-Lucas 11:00 a m Ferroptosis: New Insights and Links to Metabolism and Redox Biology -Andreas Linkermann Nephron Progenitor Fate Determination and Maintenance.......W315 Moderators: Cristina Cebrian Ligero, Lori O'Brien 9:30 a.m. Transcriptional Regulation of Nephron Progenitors – Nils Lindstrom 10:00 a.m. Nephron Progenitor Commitment Is a Stochastic Process Influenced by Cell Migration - Alexander Combes Chromatin Interactions with Transcription Factors in Progenitor Maintenance -10:30 a.m. Pin-Xian Xu Xu 11:00 a.m. Chromatin Accessibility in Progenitors – Dennis Kostka **Contemporary Management of Diabetic Kidney Disease:** Update on Recent Clinical Trials......W415 Valencia Moderators: Frank Brosius, Subramaniam Pennathur 9·30 a m SGLT2 Inhibitors - Mea Jardine 10:00 a.m. GLP1 Receptor Agonists – Daniël van Raalte Mineralocorticoid Receptor Antagonists - Peter Rossing 10:30 a.m. 11:00 a.m. ASK1 Inhibitors - Glenn Chertow Ethical Challenges in Nephrology, Including the Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy.......W304 ASN gratefully acknowledges the Northwest Kidney Centers and its contributors for support of the Christopher R. Blagg Endowed Lectureship in Kidney Diseases and Public Policy.

Dialysis for Patients in the Undocumented Immigrant Community in the United States: The Christopher R. Blagg, MD, Endowed Lectureship in

Transplanting Genetically-Modified Pig Kidneys into Humans: A Review of the

Ethical Issues in Pediatric Kidney Replacement Therapy – Aaron Wightman

Ethics of Shared Decision Making in Kidney Diseases – Sara Davison

Kidney Diseases and Public Policy – Lilia Cervantes

Ethical Challenges - Peter Reese

Moderators: Fahad Saeed, Milda Saunders

9:30 a.m.

10:00 a.m.

10:30 a.m.

11:00 a m

#### Sunday, November 6, 9:30 a.m. – 11:30 a.m.

Glomorular I	Diseases and Cancer: Cause or Effect?W414
	ovided by an educational grant from Travere Therapeutics, Inc.
	Mark Perazella, Aisha Shaikh
9:30 a.m.	Glomerular Diseases in Solid and Hematologic Malignancies: Pathogenesis,
J.30 a.iii.	Diagnosis, and Management – Pooja Amarapurkar
10:00 a.m.	Glomerular Diseases Associated with Cancer Treatment: Mechanism of Disease,
10.00 a.111.	Diagnosis, and Management – Naoka Murakami
10:30 a.m.	Screening for Cancer in Patients with Newly Diagnosed Glomerular Disease:
10.30 a.111.	When Is It Appropriate? – Emmanuelle Plaisier
11:00 a.m.	Cancer due to Immunosuppressive Therapy in Glomerular Disease: What Can
11.00 a.111.	We Do to Mitigate the Risk? – Kenar Jhaveri
	The Do to Miligate the Nisk. Relia sharen
Pending Cha	Illenges When Addressing Donor Kidney Function:
How Low Is	Low Before and After DonationW307
Moderators: I	Krista Lentine, Aneesha Shetty
9:30 a.m.	Should Optimal Pre-Donation GFR Be Based on a Single Flat Cutoff or Based on
	Age and Gender? – Emilio Poggio
10:00 a.m.	Should Donors Be Classified as Having CKD Post-Donation? – Sunita Singh
10:30 a.m.	The Hypertensive Kidney Donor: How Far to Push It? – Ann Bugeja
11:00 a.m.	Living Donor Prospective on Kidney Donation – Lacye Trevino
	echanisms of Hypertension and Cardiovascular EffectsW308
	Bryan Becker, Mahboob Rahman
9:30 a.m.	Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of
	Preeclampsia – Gene Bidwell
10:00 a.m.	Dysregulation of the Circadian Rhythm of BP Is Associated with Adverse
	Cardiorenal Outcomes – Michelle Gumz
10:30 a.m.	CKD Pathogenesis in Hypertension from Human and Animal Genomic Studies –
	TBD
11:00 a.m.	Salt-Induced BP Elevation Is Associated with Impaired Bile Acid Signaling and
	Monocyte Activation – Jeanne Ishimwe



#### 2022 ACCOMPLISHMENTS

## **Championing Kidney Care**

### INTERVENE EARLIER to prevent, diagnose, coordinate care, and educate

- Advanced support across the federal government for early kidney disease testing.
- Prioritized research of new biomarkers and health equity improvements.
- Advocated for Medicare to address the data gap in Medicare Advantage expansion and include people with kidney failure.

#### **TRANSFORM TRANSPLANT and increase access to donor kidneys**

- Collaborated with Congress, HRSA, and CMS to increase transparency, accountability, and patient-centered care in the transplantation ecosystem
- Led successful efforts to remove race factors in eGFR calculations used in the transplant process.
- Advocated for Medicare to provide dental coverage for transplant candidates, recipients, and immunocompromised patients, and supported legislation to allow purchase of dental insurance through federal health care exchanges.

#### **ACCELERATE INNOVATION and expand patient choice**

- Secured new federal funding for innovation at KidneyX, research at NIH and NIDDK. and disease surveillance at CDC.
- Advanced reimbursement for increased innovation in TPNIES and TDAPA, while developing payment pathways for an artificial kidney and other innovations.
- Addressed barriers and quality measurement in home dialysis.

#### **ACHIEVE EQUITY and eliminate disparities**

- Supported legislation to extend pandemic telehealth expansions.
- Encouraged ASN members to address the impact of climate change on kidney care.
- Outlined recommendations to increase equity and utilization of social determinants of health in kidney care, and provide regular dialysis care for undocumented individuals through Medicaid.



## LGBTQ+ Owned and Friendly Local Businesses and Organizations in Orlando

Please join ASN in supporting these local businesses and organizations.

#### Restaurants

#### Hamburger Mary's

110 W Church St 321-319-0600

#### White Wolf Café & Bar

1829 Orange Ave 407-895-9911

#### The Hammered Lamb

1235 N Orange Ave 407-704-3200

#### Café Tu Tu Tango

8625 International Dr 407-248-2222

#### **Island Time**

712 E Washington St 407-930-2640

#### **Bites and Bubbles**

1618 N Mills Ave 407-270-5085

#### **Estefan Kitchen Orlando**

3269 Margaritaville Blvd (Kissimmee) 407-828-0999

#### **Community Organizations**



#### **Bars and Clubs**

#### Southern Nights

375 S Bumby Ave 407-412-5039

#### Stonewall Bar Orlando

741 W Church St 407-373-0888

#### Latitudes

33 W Church St 407-649-4270

#### **Ember**

42 W Central Blvd 407-849-5200

#### **Savoy Orlando**

1913 N Orange Ave 407-270-4685

#### onePULSE Foundation

1912 S Orange Ave, info@onePULSEfoundation.org, 407-775-4611
The Pulse Memorial is a sanctuary of quiet reflection and love dedicated to honoring the senseless lives taken and remembering the horrible attack that occurred on June 12, 2016. ASN is making a \$25,000 donation to the foundation to demonstrate our unwavering support of the LGBTQ+
Communities. If you would like to contribute, go to https://secure.qgiv.com/for/asnone/ or text ASN to 505155 or scan this QR code.

#### Community Organizations (cont.)

#### The Center Orlando

946 N Mills Ave, info@thecenterorlando.org, 407-228-8272

We look to transform our community by inspiring and connecting people and organization, promoting acceptance and inclusion.

#### Hope & Help Center of Central Florida

4122 Metric Dr Ste 800 (Winter Park), 407-645-2577

Founded in 1988 and is the largest HIV/AIDS service and advocacy organization in the Orlando metropolitan area.

#### Zebra Coalition

911 N Mills Ave, info@zebrayouth.org, 407-228-1446

Zebra Coalition is a network of organizations which provide services to lesbian, gay, bisexual, transgender, and all youth (LGBTQ+) ages 13–24. The Coalition assists young people facing homelessness, bullying, isolation from their families, and physical, sexual and drug abuse with individualized programs to quide them to recovery and stability.

#### The Pride Chamber

5003 Old Cheney Hwy, info@thepridechamber.org, 321-800-3946

We are the LGBT Chamber of Commerce dedicated to the business equality movement in the Greater Orlando area and beyond. The Pride Chamber's strategic focus is to serve as a resource to small businesses and large corporations and bridge the gap between them. We welcome you to get engaged in our mission to strengthen equality in Greater Orlando's business community.

#### One Orlando Alliance

611 N Mills Ave Box 533005, 407-499-1711

One Orlando Alliance is a vital support network for LGBTQ+ organizations in Central Florida. We lower barriers, provide critical communication, and promote effective, influential, and sustainable opportunities for transforming the culture of the region. We understand transformative change in attitudes and behaviors begins with an unwavering commitment to bettering the welfare of all. We will achieve this by fostering a deep respect for one another and ensuring inclusiveness within our diverse population.

#### Come Out With Pride

424 E Central Blvd Ste 415 (mail only)

Come Out With Pride is an all-volunteer nonprofit organization inspired to make an impact in Orlando's LGBTQ+ community. Celebrated in October, Come Out With Pride welcomes everyone from Central Florida and beyond to come together and #KeepDancingOrlando! We are dedicated to supporting our community through grants and scholarship programs.

#### **Orlando Youth Alliance**

PO Box 536944, info@orlandoyouthalliance.org, 407-244-1222

A 501(c)(3) nonprofit organization founded in 1990. Our mission is to provide a safe space for LGBT youth in Central Florida. We meet on Tuesday evenings at 6:15 p.m. at Reeves United Methodist Church, 110 N Ferncreek Ave.

#### **MBA Orlando LGBT Chamber of Commerce**

5003 Old Cheney Hwy, info@thepridechamber.org, 321-800-3946 Dedicated to the pursuit of equality through economics.

## **ASN Innovations in Kidney Education Contest Winners**

,,,,,,,,,,

Congratulations to the winners of the 2022 ASN Innovations in Kidney Education Contest. These winners represent the best of these innovative approaches (relevance, creativity, portability, and feasibility) to teaching about kidney health and diseases.

#### kidney.wiki

Ryan Town

Stanford University Center for Academic Medicine

#### **Genomics of Kidney Disease Interactive Virtual Modules**

Mira T. Keddis, Hana Newman, Harini A. Chakkera, Kara Mangold, Filippo Pinto e Vairo, Mireille El Ters, Marie Hogan, Timothy Curry

Mayo Clinic College of Medicine (Arizona)

#### **Channel Your Enthusiasm: The Burton Rose Book Club**

Joel M. Topf, Anna R. Gaddy, Melanie P. Hoenig, Edgar V. Lerma, Sai Sudha, Priti Meena, Roger A. Rodby, Dominique Tomacruz, Juan Carlos Valez, Joshua S. Waitzman, Amy Yau

Oakland University William Beaumont School of Medicine

ASN thanks the contest judges for their review and expertise: Mark G. Parker (chair), Anna Marie Burgner, Katie E. Cardone, Denise K. Link, Rajeev Raghavan, and Hanny Sawaf

Support for the 2022 contest is provided by



## Cele's Champions: Cele Fogarty Travel Support Program for Patients

On behalf of the 850,000,000 people worldwide with kidney diseases, the Cele Fogarty Travel Support Program for Patients ("Cele's Champions") honors people living with kidney diseases or caring for an individual with kidney diseases by supporting their voice and advocacy.

Cecilia "Cele" Agnes Fogarty
was a leading executive in
event management and
member services for decades,
advancing the work of several
major organizations in health
care, medicine, science, and
other areas. She was renowned
for her ability to manage the most
complex meeting logistics, anticipate
challenges, and meet the unexpected
crises—large and small—with aplomb
and sometimes magic. Her dedication and
persistence parallel the courage and diligence to

live well with a chronic disease. Throughout her career, Ms. Fogarty mentored countless meeting and event professionals as well as other staff from not-for-profit organizations and the hospitality industry. Prior to her death in 2021, she served as ASN Vice President for Meetings and Member Experience. She and her team were responsible for managing the logistics for ASN Kidney Week, the society's other national and international events, and related activities.

Despite being diagnosed with kidney disease herself, Ms. Fogarty continued to work towards "A world without kidney diseases," including the strenuous onsite meeting management, due to the flexibility of peritoneal dialysis, and support of her care team.

## Patient advocates who speak out for the people worldwide with kidney diseases.

ASN is committed to including the patient voice throughout the organization and in its activities. To honor Ms. Fogarty, her commitment to mentorship, and her passion for accommodating all people regardless of the challenges they may face, ASN is pleased to announce the inaugural group of "Cele's Champions" – patient advocates who speak out for the people worldwide with kidney diseases.

- Lubna Akbany
- Jimmie Bates
- Marc Burling
- Nieltje Gedney
- Jackson Goodrich

- Jennifer Meyer
- Janine Reed
- Charles Rice, CPhT
- Wendy Rodgers



#### **Medical Resources and Tools:** Partnering With Experts in the Field

GSK is proud to partner with experts in the field to bring you educational resources to support you and your patients.



#### Anemia of Chronic Kidney Disease

anemiaofckdnetwork.com

Explore resources around the clinical burden and unmet needs of anemia of CKD. Learn about:

- The prevalence and burden of untreated anemia of CKD
- The potential impact of anemia of CKD on patients
- Mechanisms of disease in the pathophysiology of anemia of CKD, including the HIF pathway



### Lupus Nephritis sleeducatorsnetwork.com

Explore the latest scientific advances and expert opinion in LN

- · Learn how you can protect your patients from ESKD through earlier diagnosis and management with therapies that modify the underlying autoimmune disease
- · Understand evolving biomarkers and clinical assessments to help inform LN management
- Identify strategies to help remove barriers related to healthcare disparities in LN



Steven Fishbane, MD Northwell Health and Hofstra University, Great Neck, NY

**Exhibitor Spotlight** 

#### **Physician-Patient Discussion: Does Patient Care Need to Evolve for**

November 5, 2022 | 10:00-10:45AM Exhibit Hall - West Building

Join Dr. Steven Fishbane and Erich, a patient with anemia of CKD, as they discuss the unmet needs in anemia of CKD. We will also hear the patient perspective on the impact of anemia of CKD on daily life.





Come visit us at BOOTH #1707 and engage with:

- Interactive content for:
- Anemia of Chronic Kidney Disease (CKD)
- Lupus Nephritis (LN)
- Respiratory Syncytial Virus (RSV)
- Hemoglobe Immersive Augmented Reality Experience
- · Anemia of CKD Virtual Reality House
- LN Challenge
- Expert Forums



